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The toxicity of Gram-negative bacterial endotoxin (lipopolysaccharide, LPS) resides 
in its structurally highly conserved glycolipid component called lipid A. The major 
goal of the first project was to further explore structure-activity relationships in small-
molecules that would sequester LPS by binding to the lipid A moiety, so that it may 
find application in the prophylaxis or adjunctive therapy of Gram-negative sepsis. 
Several guanylhydrazones had earlier been identified in rapid-throughput screens as 
potent LPS binders. It was desirous to examine if grafting the guanylhydrazone 
functionality on the scaffold of a lead N-alkyl polyamine compound would afford 
greater LPS sequestration potency. In the first project, a congeneric set of 
guanylhydrazone analogues were synthesized and evaluated for LPS-sequestering 
potency. It was found  that a C16 alkyl substitution was optimal in the N-
alkylguanylhydrazone series; a homospermine analogue with the terminal amine N-
alkylated with a C16 chain with the other terminus of the molecule bearing an 
unsubstituted guanylhydrazone moiety was marginally more active suggesting very 
slight, if any, steric effects. Neither C16 analogue was significantly more active than 
the N-C16-alkyl or N-C16-acyl compounds that we had characterized earlier, indicating 




The N-terminus of bacterial lipoproteins are acylated with a (S)-(2,3-
bisacyloxypropyl)cysteinyl residue. Lipopeptides derived from lipoproteins activate 
innate immune responses by engaging Toll-like receptor 2 (TLR2), and are highly 
immunostimulatory and yet without apparent toxicity in animal models. The 
lipopeptides may therefore be useful as potential immunotherapeutic agents. Previous 
structure-activity relationships in such lipopeptides have largely been obtained using 
murine cells and it is now clear that significant species-specific differences exist 
between human and murine TLR responses. In the second project, I have examined in 
detail the role of the highly conserved Cys residue as well as the geometry and 
stereochemistry of the Cys-Ser dipeptide unit. (R)-diacylthioglycerol analogues were 
maximally active in reporter gene assays using human TLR2. The Cys-Ser dipeptide 
unit represents the minimal part-structure, but the stereochemistry of neither amino 
residues of the dipeptide was found to be a critical determinant of activity. The 
thioether bridge between the diacyl and dipeptide units was determined to be crucial, 
and replacement by an ether bridge resulted in a dramatic decrease in activity. 
Moreover, the replacement of the two ester-liked C16 hydrocarbons by ether or amide 
linkages led to a dramatic loss in activity, while the replacement of one of the ester-
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Chapter 1  
Introduction: Gram-negative Sepsis 
 
1.1 Background. 
     Gram-negative sepsis, or "blood poisoning" in lay terminology, is a common and 
serious clinical problem. While fewer than 100 cases were reported prior to 19201, it 
is now the thirteenth leading cause of overall mortality2 globally, and the number one 
cause of deaths in the intensive care unit3 accounting for some 200,000 fatalities in 
the US annually4 (Figure 1). While the incidence continues to rise worldwide5;6 due 
to increased invasive procedures, immunosuppression and cytotoxic chemotherapy, 
mortality has essentially remained unchanged at about 45%7 due to the lack of 
specific therapy aimed at the pathophysiology of sepsis.  



























         Figure 1.  Incidence of Sepsis in the U.S. Data provided by Greg Martin.5,6 
     The primary trigger in the gram-negative septic shock syndrome is endotoxin, a 
constituent of the outer membrane of all gram-negative bacteria. Endotoxins consist 
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of a polysaccharide portion and a lipid called lipid A, and are therefore also called 























     The polysaccharide portion consists of an O-antigen-specific polymer of repeating 
oligosaccharide units, the composition of which is highly varied among gram-
negative bacteria. A relatively well-conserved core hetero-oligosaccharide covalently 
bridges the O-antigen-specific chain with the structurally highly conserved lipid A8;9. 
Lipid A is the active moiety of LPS9;10 and is composed of a hydrophilic, negatively 
charged bisphosphorylated diglucosamine backbone, and a hydrophobic domain of 6 
(E. coli) or 7 (Salmonella) acyl chains in amide and ester linkages  (Figure 2).11-13 
     Whereas LPS itself is chemically inert, the presence of LPS in blood  
(endotoxemia), often a consequence of antibiotic therapy of preexisting bacterial 
infections, sets off a cascade of exaggerated host responses, which under normal, 
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Figure 2. Schematic (left) and crystal structure (middle) of lipopolysaccharide (LPS). 
Shown on the right is the structure of enterobacterial lipid A. 
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homeostatic conditions serve to orchestrate innate immune defenses. It is the 
uncontrolled, overwhelming, and precipitous systemic inflammatory response that 
ultimately manifests clinically in the frequently fatal shock syndrome characterized 
by endothelial damage, coagulopathy, loss of vascular tone, myocardial dysfunction, 
tissue hypoperfusion, and multiple-system organ failure.14 LPS activates almost every 
component of the cellular and humoral  (plasma protein) limbs of the immune system 
(Figure 3), resulting in the production of a plethora of proinflammatory mediators, 
important among which are the cytokines tumor necrosis factor  (TNF-), 
interleukin 1  (IL-1), and IL-6, secreted mainly by monocytes and macrophages  
(M).15 These cytokines and other mediators act in concert, amplifying the resultant 
Figure 3. Schematic representation of immune activation by LPS 
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generalized inflammatory processes. Endotoxemia and its deleterious sequelae may 
arise even in the absence of systemic gram-negative bacterial infections; conditions 
such as trauma16, burns17, and splanchnic ischemia during cardiac surgery18 or gram-
positive sepsis19 increase intestinal permeability, resulting in the spill-over into the 
portal circulation of LPS from the colon which is abundantly colonized by gram-
negative bacteria.  
     Our understanding of basic mechanisms underlying the cellular response to LPS 
has increased vastly in recent years. Important research contributions include LPS 
recognition20 by CD1421-24  [and other cell surface recognition molecules]25;26 via an 
LPS-binding acute-phase plasma protein (LBP),27-29 initiation of signal transduction 
by toll-like receptor-430;31, and downstream cellular activation events mediated by 
mitogen-activated kinase p38 and c-Jun N-terminal kinase, leading to nuclear 
translocation of NF-B32;33-35 resulting in cytokine mRNA transcription. These 
advances will likely offer novel therapeutic possibilities in the future.  However, after 
more than two decades of intensive effort at evaluating more than 30 investigational 
compounds, specific therapeutic options for sepsis have remained elusive. On June 
29, 2000, Eli Lilly announced that favorable results had been obtained in Phase III 
clinical trials for Xigris™ (recombinant human activated protein C), an anticoagulant 
that targets a component of the humoral activation pathway and ameliorates 
disseminated intravascular coagulation. Clinical trials of recent years aimed at 
blocking various proinflammatory mediators including TNF-, IL-1, platelet-
activating factor, and prostaglandins produced by the activated cellular components 
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have all been disappointing36 (Figure 4), suggesting that targeting downstream 
cellular inflammatory processes once immune activation has already progressed is 
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Figure 4. Outcomes of clinical trials of anti-inflammatory agents in 
sepsis. Adapted from Zeni et al., 1997 (Ref. 37). 
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1.2 Complexation of LPS by Macromolecules as a Therapeutic Strategy. 
1.2.1 Polyclonal and Monoclonal Antibodies: As mentioned earlier, the       
polysaccharide portion of LPS is extremely variable and serologically distinct for 
each strain of the same species of gram-negative organisms. Although anti-O-
polysaccharide antibodies afford protection in experimental models where animals 
are challenged with homologous bacteria37, these are not likely to be of significant 
clinical value since sepsis runs an acute course before the pathogen is identified and 
appropriate specific immunotherapy is instituted. The biologically active part of LPS, 
lipid A, as well as the core oligosaccharide portion are structurally highly conserved 
across gram-negative genera, and thus are attractive targets for sequestration, and 
elimination of circulating LPS would, in principle, prevent the activation of 
inflammatory cascades. Experimental studies as early as 1968 suggested that 
antibodies directed toward epitopes in the core region of LPS may be broadly cross-
protective against a range of gram-negative organisms. However, neither human (HA-
1A)38 nor murine (E5)39 anti-lipid A monoclonal antibodies afforded significant 
protection in large, multiple, placebo-controlled clinical trials.7 In the wake of these 
failures, it became apparent that these monoclonal antibodies had been expedited 
through clinical trials without rigorous preclinical evaluation. Both HA-1A and E5 
exhibited low intrinsic binding affinities to LPS40 (<104 M-1), neutralized LPS poorly, 
bound promiscuously to a wide range of hydrophobic ligands such as lipoproteins and 
cardiolipin, as well as to a variety of human B cell and erythrocyte proteins,41 and 
proved to be toxic in a canine model of septic shock. Although the validity of 
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circulatory LPS as a therapeutic target is still viable, and efforts at developing core 
region-directed antibodies continue42,43 disappointing results obtained thus far could 
point to intrinsic problems with lipid antigens: poor immunogenicity, inaccessibility 
of neutralizing epitopes, the generation of nonspecific cross-reactive antibodies 
against irrelevant hydrophobic epitopes44, and potential problems with the antibody 
molecule itself: predominant intravascular compartmentalization, and possible tissue 
damage induced by activation of complement. Other immunotherapeutic strategies 
include the blockade of LPS binding to CD14 (the predominant cell-surface receptor 
for LPS) with anti-CD14 antibodies45;46 or anti-LBP antibodies.47 
 
1.2.2 Non-Antibody LPS-binding Proteins: The approach of neutralizing LPS or 
preventing cellular recognition by its cognate receptor (s) using non-antibody protein 
macromolecules is being actively pursued48, and notable developments in the area is 
bactericidal/permeability-increasing protein (BPI), a neutrophil azurophilic granule-
derived, antibacterial protein involved in innate host defense.49-51 On September 14, 
2000, Xoma Inc. announced favorable results of rBPI21 in preliminary clinical trials 
of severe pediatric meningococcemia, and has since obtained an FDA Subpart E 
designation for Phase III trials. Further ongoing trials will likely provide valuable 
data on the clinical efficacy of LPS neutralization by large, protein macromolecules 




1.3 The Paradigm of Non-immunologic Sequestration of LPS by Small Molecules 
1.3.1 Polymyxin B: The structurally invariant and biologically active center of LPS, 
lipid A, is a logical therapeutic target for neutralization. The anionic amphiphilic 
nature of lipid A enables it to interact with a variety of cationic hydrophobic 
ligands.52-55 Polymyxin B (PMB), a cationic amphiphilic cyclic decapeptide antibiotic 
isolated from Bacillus polymyxa53 has long been recognized to bind lipid A,54 and 
neutralize its toxicity in vitro and in animal models of endotoxemia.55-56;57 PMB has 
served as a "gold standard" for endotoxin-sequestering agents and is routinely used in 
experimental studies when a biological effect is to be verified as that due to LPS, or 
to abrogate activity of contaminating LPS. Listed in the US Pharmacopeia as a topical 
antibiotic, PMB is too toxic for parenteral use, which, while precluding its utility as 
an LPS-neutralizer in patients with sepsis, has stimulated the search for nontoxic 
PMB analogs58, PMB derivatives59-60 as well as other structurally diverse cationic 
amphiphilic peptides61;620, as candidate LPS-binding agents which are yet to be 
evaluated in clinical trials. A cartridge based on polymyxin B covalently immobilized 
via one of its NH2 groups to a polystyrene based fiber became available in Japan in 
late 2000 for clinical use (“Toraymyxin”, Toray Industries Inc., Tokyo).63-66 While 
this provides a clinically validated proof-of-principle for the value of sequestering 
circulating LPS, opportunities for extracorporeal hemoperfusion are rare: the typical 
patient is often profoundly hypotensive, with circulatory failure, refractory even to 
maximal vasopressor and intravenous fluid therapy regimens, underlining the need to 
develop alternate strategies for LPS sequestration.  
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     The solution structure of PMB has been determined both in its free, aqueous,  
(Figure 5) as well as LPS-bound states.67;68  The cyclic moiety of aqueous PMB in its  
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Figure 5. Solution structure (top left), primary structure of Polymyxin B (PMB) (top 
right), NMR-derived conformation of the lipid A: PMB complex (bottom left) Arrows 
indicate salt-bridges. The methyloctanoyl acyl moiety attached to Dab1 is oriented 
normal to the plane of PMB. Bottom Right: Detail showing bidentate ionic H-bonds 
(dotted lines) between Dab sidechain pairs of PMB and the phosphates of lipid A (only 
glycosidic backbone is shown). 
 -NH2: Dab
3




unbound form is characterized by a type II' -turn centered at D-Phe5, and a  turn at 
Thr9 with no transannular H-bonds, features that are preserved also in the LPS-bound 
form. In the lipid A-PMB complex, (Figure 5) the carbonyl groups form a polar 
surface on one face of the cyclic portion which overlies the glycosidic hydrophilic 
backbone of lipid A, and the linear part, bearing the hydrocarbon chain, is parallel to 
the long axis of lipid A, and is apposed to the acyl chains of lipid A, the basis of the 
hydrophobic interaction of the peptide with LPS. The -NH2 groups of pairs of the 
Dab residues (Dab3/Dab4 and Dab7/Dab8) form bidentate ionic H-bonds with the lipid 
A phosphates (Figure 5).  
 
1.3.2 Structural correlates of affinity of LPS binding in nonpeptide small 
molecules: A number of classes of cationic amphiphilic drugs already in therapeutic 
use were screened for lipid A binding and LPS neutralization, among them 4-
aminoquinoline antimalarials, phenothiazine antipsychotics, biguanide 
hypoglycemics, the bis-diguanide antimicrobial, chlorhexidine, and the diamidine 
antiprotozoal, pentamidine. The criteria for selection of these classes was simply that 
these drugs were cationic amphiphiles.69 It was noted from these early, exploratory 
studies that dicationic bolaamphiphiles such as pentamidine and chlorhexidine bound 
lipid A strongly with apparent Kd values of 0.12 and 0.87 M, respectively, the Kd for 
PMB, the reference compound being 0.37 M  (Figure 6). The bisguandine, 
chlorhexidine, bound lipid A with an affinity about 80 times that of the 
monobiguanides, metformin and phenformin, and the Kd of pentamidine was greater 
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than that of PMB (Figure 6). Both compounds antagonized LPS activity in the 
Limulus (horseshoe crab) amebocyte lysate gelation assay, an extremely sensitive in 
vitro test with a detection limit of 1 ng/mL of uncomplexed, bioactive LPS.69 This 
was the first indication that the presence of two basic groups separated by a distance 
could be a correlate of high binding affinity.  
 
1.4 Structural Correlates of LPS Binding and Neutralization. 
1.4.1 Elucidation of the pharmacophore for lipid A binding: The amidinium  
(pentamidine) and guanidinium (chlorhexidine) groups are also strongly basic 
protonatable functions (see Figure 6) and it was therefore of interest to systematically 
examine the effect of varying inter-cationic distance and basicity  (pK) of the cationic 
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Figure 6. Left: Affinity of cationic amphiphilic drugs toward lipid A measured by DC 
displacement. Legends (and corresponding structures) are shown right of graph.  
Right: Analogs of pentamidine: imidazolino-pentamidine, berenil, methoxy-
pentamidine, propamidine (top to bottom). The affinity of all these analogs was 
identical to that of pentamidine.  
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groups in model dicationic molecules.70 ,-Diaminoalkanes, the polyamines 
spermidine and spermine and their derivatives constituted a set of simple, linear 
molecules with inter-NH2 distances ranging between 5-16 Å (obtained by molecular 
modeling assuming extended conformations); N1- and N8-monoacetylated 
spermidine, and N4-benzylspermidine were used to test the importance of two 
cationic functions, and the possible role of bulky, hydrophobic nonterminal 
substituents, respectively. Comparisons of spermidine and N1, N8,-
diguanidospermidine (synthesized from spermidine using O-methylisourea) allowed 
the exploration of the hypothesis that basicity impacted upon augmented binding 
affinity. Pentamidine analogs shown in Figure 6 constituted another set of molecules 
with varying inter-cationic distance (Berenil: 12.82 Å - Pentamidine: 19.56 Å). The 
electron-donating methoxy group ortho to the amidinium function decreases its pK, 
and the imidazolino group is considerably less basic than the amidinium group 
(Figure 6). In brief, the findings were:  (a) The affinities of N1- or N8-monoacetylated 
spermidine were about 1/80th of spermidine, indicating that the presence of two 
cationic functions corresponded to enhanced affinity; (b) the affinity of 4-
benzylspermidine toward lipid A is about 2.4 times less than that of spermidine 
suggesting that nonterminal bulky "pendant" groups may sterically hinder 
complexation;  (c) a distinct sigmoidal relationship between intercationic distance and 
affinity toward lipid A was observed, with a sharp increase from 11Å, leveling off at 
about 13Å (Figure 7). This coincides, within experimental error, to the inter-
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structure of LPS  (13.9Å);  (d) pentamidine, and its methoxy- and imidazolino- 
analogs bound lipid A with identical affinity, as did spermidine and N1, N8-
diguanidospermidine, indicating that the pK of the terminal cationic function is not 
critical in determining binding affinity. However, the electrostatic interactions of 
































Figure 7. Relationship between inter-nitrogen distance of -diaminoalkanes, 
polyamines, and bisamidines, and binding affinity to lipid A. The inflection point of the 
sigmoidal curve coincides with the inter-phosphate distance of lipid A (inset). Relative 
affinity is represented as fold affinity w.r.t. diaminopropane. 
ionic H-bonds (salt-bridges) since several compounds with quaternized 
polyamidinium functionalities did not bind endotoxin  (data not shown). 
     The pseudo-bichromophoric nature of pentamidine  (see structure in Figure 6) 
ascribes unique photophysical properties, which were exploited in characterizing the 
mode of binding and nature of the drug-lipid A complex.70 Upon binding of 
pentamidine to lipid A [and not to other polyanions such as DNA71 that the drug is 
known to bind to], a unique emission band appears in the fluorescence spectrum 
which was ascertained to be due to inter-molecular excimer formation70, a 
consequence of the unique geometry and orientation of the chromophores in the 
pentamidine-lipid A complex. Under conditions when lipid A is completely 
monomeric  (in CHCl3/MeOH) pentamidine binds specifically to diphosphoryl, and 
not to monophosphoryl lipid A, with a 1:1 stoichiometry, indicating the bisamidine 
simultaneously recognizes the two anionic phosphates on the ends of the glycosidic 
backbone of lipid A70  (data not shown). The recognition of the phosphate group by 
the amidine is not sensitive to the specific orientation of the glycosidic 1-phosphate  
(which is thought to be an important determinant of biological activity of lipid A)8 
since both the - and -anomeric forms of phosphonooxyethyl analogs of synthetic 
lipid A [provided by S. Kusumoto72] are bound by pentamidine (data not shown). The 
interaction of the drug with the toxin is almost exclusively electrostatically driven, 
with negligible hydrophobic components, and is dependent on the ionization state of 
both the amidine and the phosphate, since protonation of either the lipid A phosphates 
(pH<5) or deprotonation of the amidinium groups of the drug (pH>10) results in 
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destabilization of the complex (data not shown). An energy-minimized model of the 
pentamidine: lipid A complex, derived from extensive biophysical characterization of 
the interactions is represented in Figure 8, showing the orientation of the drug with 
respect to lipid A, and the salt-bridges between the lipid A phosphate and the 
amidines. The model facilitates the consideration of possible sites of introducing 
sterically favorable hydrophobic groups that would be expected to enhance the 
entropic contributions of the free energies of interaction. 
 
 
Figure 8. Model of the pentamidine (van der Waals surface): 
bis-phosphoryl lipid-A complex (sticks). The P atoms of lipid 
A are space-filled. 
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1.4.2 Lipid A binding is necessary, but not sufficient for LPS neutralization: That 
the recognition of LPS and subsequent binding by LPS-binding molecules does not 
necessarily result in inhibition of endotoxic activity can be adduced from the 
literature. For instance, LPS-binding protein  (LBP)27, an acute phase-reactant plasma 
protein synthesized by the liver under conditions of stress73, and the neutrophil 
granule-derived bactericidal/permeability increasing protein (BPI) are highly 
homologous in their sequences74;75 and bind LPS competitively76 with comparable 
affinities. Yet, whereas LBP "opsonizes" LPS77, and presents it to CD1478;79 initiating 
LPS-induced cellular activation processes80, the binding of BPI to LPS results in 
neutralization of endotoxic activity.81;82 Attempts at understanding the structural basis 
of this important functional difference led to the elucidation of high-resolution crystal 
structures of BPI83 and a Limulus (horseshoe crab) endotoxin binding protein 84 
(ENP).85;86 Another pertinent example is that of polymyxin B (PMB). It has been 
known for about a decade87 that polymyxin nonapeptide (PMN), with a single fatty 
acyl-Dab residue removed from its decapeptide parent molecule is virtually bereft of 
endotoxin-neutralization activity. PMB and PMN bind lipid A and LPS with identical 
affinities, and behave indistinguishably in a variety of spectroscopic assays designed 
to probe ligand-induced fluidity changes of the acyl domains of lipid A, bilayer-to-
nonlamellar phase transitions, and neutralization of the electrostatic double layer of 
lipid A or LPS aggregates.88 These data, taken together, point to the importance of 
stabilization of ligand-LPS complexes by hydrophobic interactions, a premise which 
has been examined for PMB using techniques such as surface plasmon resonance89 
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and titration calorimetry.90 The lack of comparison, however, for PMB and PMN in 
these studies90;91 has not yet permitted a complete and formal verification.      
     Pentamidine is an excellent case in point illustrating the binding is necessary, but 
not sufficient for neutralization. Whereas it binds LPS with an affinity even greater 
than that of PMB, only feeble inhibition of cytokine (Tumor Necrosis Factor-alpha; 
TNF-) release from LPS-stimulated human mononuclear cells was observed (Figure 
9) and did not protect mice against lethal doses of LPS. 
 



















Figure 9. Inhibition of TNF- in LPS (10 ng/mL)-stimulated human PBMC 
by pentamidine (hatched bars) and polymyxin B (solid bars). Note that 
inhibition by pentamidine is partial even at the highest concentration (10 
g/ml)  
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1.4.3 Structural correlates of neutralization of endotoxicity. The obligatory 
requirement of a hydrophobic moiety:  Having identified that the presence of two 
protonatable cationic groups positioned about 14 Å apart in a linear molecule was 
sufficient to ascribe high-affinity binding to LPS, and an additional hydrophobic 
moiety was necessary for the binding to result in neutralization of endotoxic activity  
(sequestration), experiments using the polyamines, spermidine (~ 11 Å; sub-optimal 
length), spermine (~16 Å, optimal length), and their monoacylated analogs92  (Figure 
10) were performed. Spermine was inactive while the acylated polyamines inhibited 
TNF- release in a dose-dependent manner, the longer homologated spermine analog  
(Compound B) being more active than the monoacylated spermine analog [one 
terminal protonatable amine function is lost]  (Compound A, Figure 10) confirming 





Figure 10. Structures of acylpolyamines (left), and inhibition of TNF- 
induction in J774 cells stimulated with 25 ng/mL LPS (right). Essentially 
identical results were obtained with RAW cells. Similar inhibition profiles were 






















































clear structural leads in efforts to recognize simple molecules that would behave as 
endotoxin sequestrants, and importantly, led to the identification of the 
pharmacophore for LPS-sequestration.  
 
1.5 Lipopolyamines as Lead Compounds for Development of LPS Sequestrants.  
es as potential endotoxin sequestering 
: An optimal distance of ~14 Å is necessary between protonatable 
cient for activity, and an additional, 
appropriately positioned hydrophobic group is obligatory for the interaction to 
manifest in neutralization of endotoxicity.101;102 
     The structural features that we had identified to be important in conferring LPS-
sequestering properties are to be found in lipopolyamines, members of a burgeoning 
class of cationic lipid molecules designed to facilitate transfection of DNA into 
eukaryotic cells, now receiving increasing attention because of interest in human gene 
therapy.93-94;95 These molecules are of particular interest since they are designed to be 
of low toxicity to mammalian cells, and are being approved by the FDA for human 
use as safe alternatives to viral vectors.96-97;98 
     Our proposal of evaluating lipopolyamin
molecules was based on two simple heuristics which had been experimentally 
validated:  
Heuristic 1
functions in bis-cationic molecules for simultaneous ionic interactions with the 
glycosidic phosphates on lipid A, it is the bis-cationic scaffold that is the principal 
determinant of binding affinity (Figure 7).99;100  
Heuristic 2: Binding is necessary, but not suffi
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     For the sake of brevity, salient aspects of key structure-activity relationships in one 
homologous series of twelve mono- and bis-acyl homologated spermine analogs 














     Two questions were addressed in this study: (i) what is the optimal hydrophobic 
hain le al bis-acyl 
ermines more effective than mono-acyl compounds. It was found that a carbon 
 between ~1-2 M, while only the 
c ngth for effective anti-endotoxic activity, (ii) are symmetric
sp
number of 14-16 was optimal in mono-acyl spermines (Figure 12) which were in 
general, as potent as their bis-homologs and, in addition, showed lower surface 
activity (lower nonspecific cytotoxicity). 
     In comparing the NO and TNF- inhibition profiles with the LPS-binding 
affinities for this congeneric series, with the exception of 1a, all of the other mono-
acyl compounds bound LPS with ED50 values
longer acyl chain compounds (1d-f) were biologically active (Figure 12). This result 
emphasized the necessity of employing a biological primary screen in tandem with 
the displacement assay in order to derive reliable structure-activity relationships in 
2
O . 4CF3COOH
1a, n = 0; 1b, n = 7; 1c, n = 8;















2a, n = 7; 2b, n = 8; 2c, n = 10;
2d, n = 12 ; 2e, n = 14; 2f , n = 16
n
n
Figure 11. Structures of mono- and bis-acyl polyamine analogs.105 
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LPS-sequestering compounds. The apparent inverse correlation between ED50 and 
neutralization potency for the bis-acyl 2 series was simply a consequence of the poor 
solubility of these homologues. Free aqueous concentrations of the bis-acyl 
compounds were progressively retarded with increasing chain length, diminishing 
binding and, consequently, neutralization (Figure 12). The protective effects of 1e 
(the most potent com ound in the human TNF- inhibition assay), 2a (most active in 
inhibiting NO release in J774A.1 cells), and 2c (which was of lower potency than 
either 1e or 2a in both assays) were characterized in a murine model of endotoxemic 
p
























































Figure 12. Correlation between carbon number of the hydrocarbon group in 
mono- (open stars, dotted line) and bis-acyl (closed stars, solid line) and TNF- 
inhibition in human blood (top) and NO inhibition in murine J774A.1 cells 
(bottom). Data represent means of duplicate values obtained from a 
representative experiment. 
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sepsis. A supralethal dose (2X the dose causing 100% lethality) of 200 ng/mouse of 
LPS was administered intraperitoneally (i.p.) and separate i.p. injections of graded 
doses of compound were injected, and lethality was observed at 24 h. As is evident 
from Table 1, a clear dose-response was observed, with 1e affording complete 
protection at the 100 or 200 g/mouse dose, and partial protection at the 50 g dose. 
Both the bis-compounds were found to be inferior to 1e, suggesting that in vitro 





Compound  Compound Dose 
 mouse) 1e 2a 2c (µg /
200 0/5* 1/5* 1/5* 
100 0/5* 4/5 2/5 
50 2/5 5/5 4/5 
10 5/5 5/5 4/5 
0 5/5 5/5 5/5 
 
 
Table 1 -dependent protection of CF-1 mice challenged with a supralethal dose of 
200 ng/m e of LPS (LD100 = 100 ng) by the acylhomospermines in cohorts of five 
animals. Lethality was recorded at 24 h post-cha e. Ratios denote d/total. 












Structure-Activity Relationships of Lipopolysaccharide Sequestration in  
Guanylhydrazone-bearing Lipopolyamines 
 
2.1 Introduction and Rationale. 
     Our identification of the lipopolyamines as potential endotoxin-sequestering 
molecules was based on two simple heuristics that have been experimentally tested 
and validated99;100;103-106: (a) an optimal distance of 14 Å is necessary between 
protonatable functions in linear bis-cationic molecules for simultaneous ionic 
interactions with the anionic phosphates on lipid A (Figure 13), and (b) additional, 
appropriately positioned hydrophobic group(s) are obligatory for the interaction to 
manifest in neutralization of endotoxicity. Leads obtained from high-throughput 
screening on focused libraries107-109 as well as from molecular modeling and in silico 
docking studies110 suggested that a long-chain alkyl, rather than an acyl group that we 
had previously characterized103 may allow for more favorable electrostatic 
interactions with the lipid A phosphate groups. Independent SAR leads obtained in 
iterative rounds of screening focused libraries104;108;111-115 have all converged on 
molecules bearing a homologated spermine (homospermine) scaffold.  However, we 
had identified in such screens several guanylhydrazones as potent LPS binders.108 We 
were desirous of (i) determining if the SAR pertaining to the hydrophobic substituent 
derived for the acylpolyamines103 would also hold for molecules with similar 
 39
homospermine scaffolds grafted with guanylhydrazone functionalities, (ii) if the 
presence of the guanylhydrazone lity would afford greater LPS 
 versus 
unsubstituted guany erential endotoxin 
eutralization activities due to possible steric effects.  In order to examine these 
ic set of guanylhydrazone analogues (Figure 13).  
showing bi
 functiona
sequestration potency owing to reasons mentioned earlier, and (iii) if N-alkyl
lhydrazone compounds would manifest in diff
n

















Figure 13. Left: Molecular model of a mono-homologated, mono-alkyl polyamine 
docked on LPS, dentate ionic H-bonds with the lipid A phosphate 
groups and the external amines, as well as the carboxylates of the KDO sugars of 
the core-glycolipid, with the internal amines. Right: Structures of designed series 










































2.2 Syntheses of Compounds Bearing Alkylguanylhydrazone on One End   
      and a Free Amino Groups at the Other Terminus. 
     The syntheses of the 8 series involved a straightforward condensation of either 
commercially-available aminoguanidine 3a or N-alkylhydrazinecarboximidamides 
3b-g with the N1,N2,N3,N4-tetraBoc-protected spermine-propanal precursor (6). N-
alkylhydrazinecarboximidamides were synthesized via S-methylation of 
hydrazinecarbothiamide, followed by displacement with the corresponding 
alkylamine (Scheme 1). N1,N2,N3-triBoc-protected spermine 4, synthesized as 
repor  
amin  
the corresponding aldehyde 7a-g were 
obtained in good yields via condensation of 6 with 3a (aminoguanidine) or 3b-g. The 
Boc groups were finally deprotected with TFA to afford the target compounds as 
orangish-yello me 2). 
.3 Synthesis of Analo ring an N-alkyl Substituent on One End and an 
nsubstituted Guanylhydrazone at the Other Terminus. 
   The synthesis of 14 (Scheme 3), bearing an N-alkyl substituent on one end and an 
nsubstituted gu zone on the other terminus was carried out starting from 
1,N2,N3,N4-tetraBoc-protected spermine (9). N-Alkylation with n-C16H33I was 
arried out in the presence of NaH; the mono N-alkylated precursor 10 was isolated 
nd subjected to N-alkylation on the other terminus with 3-bromopropoxy-tert- 
ted earlier103;113;114 was N-alkylated with 3-bromopropan-1-ol, and the secondary
e was Boc-protected in a one-pot procedure. The alcohol 5 was then oxidized to

































Reagents and conditions: a. (i) 3-bromopropan-1-ol, K2CO3, DMF, 60
oC, 24 h;
(ii) Boc O (excess), MeOH, r.t., 12 h;
b. PCC, DCM, r.t., 4.5 h;
































































































Reagents and conditions: a. MeI, EtOH, 60 oC, 30 min;
Boc



































































Reagents and conditions: a. C16H33I, NaH, DMF, 0
oC-r.t., 20 h;
b. 3-bromopropoxy-tert -butyl-dimethylsilane (excess), NaH, DMF, 0 oC-r.t., 20 h;
c. (i) TBAF (1 M in THF), 2 h; (ii) PCC, DCM, r.t., 4.5 h;
d. 3a (aminoguanidine) , CH3COOH (cat.), EtOH, 85
oC, 2 h;


























































utyldimethylsilane. Sequential deprotection of the TBDMS (tert-butyldimethylsilyl) 
roup, oxidation of the resultant alcohol to the aldehyde, condensation with 


























































Figure 14. Comparison of activities of the guanylhydrazone compounds 
according to the IC50 of NF-B and NO inhibition. 
 
s mentioned earlier, several guanylhydrazones had been identified in rapid-
roughput screens in focused libraries as potent LPS binders.108;116 Guanidines and, 
y extension, guanylhydrazones, are thought to interact with phosphate groups very 
vorably via bidendate H-bonds by virtue of their planar geometry and multiple H-
ond donor N-atoms (the ‘arginine fork’ principle117), which is not possible in the 








that we have hitherto characterized.103;104;113;114;118 Since virtually all of our screening 
sults point to superior LPS recognition by homospermine scaffolds, one of the 
search objectives was to ‘graft’ guanylhydrazone functionalities on such a scaffold. 
 was of interest to examine if substantial differences in activities would be apparent 
 compounds with an N-alkylated guanylhydrazone functional group on one end and 
 free primary amine on the other or, conversely, an unsubstituted guanylhydrazone 
n one terminus, and an N-alkylated secondary amine on the other.  
   In the NF-B reporter gene assay performed in TLR4-expressing HEK cells, a 
istinct enhancement in LPS-neutralizing potency with increasing alkyl chain lengths 
 the 8 series of compounds was observed, with the optimal chain length being 
exadecyl (8f); this SAR is virtually identical to that observed with the 
cylhomospermine compounds that we had examined earlier,103 which suggests that a 
16 hydrocarbon chain is optimal for maximal interactions with the polyacyl domain 
f lipid A.119 The activity of compound 14, also with a hexadecyl substituent on the 
rminal amine rather than on the guanylhydrazone, was no different than that of 8f 
within the icate 
on the cationic termini do not adversely affect Coulombic 















 limits of statistical significance (Figure 14). This would appear to ind
























































in human blood measured by multiplexed cytometric bead array assay. Results of a 
single representative experiment is shown. 
 
8f Dose (µg / 
mouse) 











     Given the minor differences in potency between 8f and 14, we elected to 
haracterize 8f in greater detail because of a higher toxicity for 14 in in vitro cellular 
ssays (data not shown). As expected, 8f inhibits, in a dose-dependent manner, LPS-
duced proinflammatory cytokine production in whole human blood ex vivo (Figure 
5); the IC50 values in human blood are considerably higher than in the NF-B assay 
erhaps due to the fact that these compounds are bound to albumin strongly (work in 
rogress) and albumin concentrations abound in the milieu of whole blood. 
ompound 8f also affords dose-dependent protection against lethal endotoxemic 
hallenge in a murine model (Table 1), as we have observed with 
cylhomospermines.103 
.5 Conclusions. 
     We find that, as for the acylhomospermine compounds, the C16 alkyl chain is 
optimal in the N-alkylguanylhydrazone series; a homospermine analogue with the 
terminal amine N-alkyl ai  the molecule 
bearing an unsubstituted guanylhydrazone moiety is marginally more active 
suggesting very slight, if an eric effects. Neit 16 analogue is significantly 
ore active than the N-C16 yl
114 or N-C16-a  compounds that we had 
ell as a 












ated with a C16 ch n with the other terminus of
y, st her C
-alk cyl103m




     It was of particular interest to examine if 8f with its considerably higher pKa than 
tioned homospermine leads. These data, collectively, have 
ow led us to consider the exploration of analogues with multiple electron-donating 
cent to the amines on the scaffold; such compounds are expected to 
an amine, planar geometry and multiple H-bond donor atoms, would be more potent 
than the N-acyl103- and N-alkyl-114 homospermine leads that are currently in 
preclinical development.  Although much to our disappointment, no discernible 
differences in potency between these compounds in a battery of in vitro as well as 
animal experiments (data not shown) were observed, these results are, nonetheless, 
instructive in that they indicate that basicity of the terminal cationic functionality, per 
se, is not a determinant of LPS-sequestering activity, and that no increments in 
activity are to be gained by incorporating strongly basic functional groups. Indeed, 
preliminary acute toxicity studies in rodents indicate that 8f is considerably more 
toxic than the aforemen
n
groups placed adja
be considerably less basic. 
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2.6 Experimental Data. 
2.6.1 Experimental Procedures 
2.6.1.1 Syntheses of compounds bearing alkylguanylhyrazone on one end    






General Procedure for the Syntheses of Compounds 3b-g.120  
A solution of hydrazinecarbothioamide (1; 20.0 g, 219.4 mmol) in anhydrous ethanol 
(200 mL) was brought to 60 oC and methyliodide was added.  After stirring for 30 
min, the reaction suspension was filtered and white solid was yielded as compound 2.  
The white solid was washed
N
H
 with ether (46.9 g, 91%).  A solution of compound 2 (1.0 
eq.) and the corresponding amine (1.0 eq.) in ethanol was heated under reflux for 1.5 
h. The solution was cooled and diluted with ether, giving a gummy pink precipitate.  
The crude product was extracted with hot ethanol and concentrated under reduced 
pressure and the residue was recrystallized from CH3NO2 to yield compound 3b-g 
(23-53%). Representative data for the series are given below. 3b: 1H NMR (400 
MHz, MeOD) δ3.17-3.25 (m, 2H) , 1.55-1.66 (br m, 2H) , 1.26-1.45 (m, 10H), 0.86-
0.97 (m, 3H). 13C NMR (126 MHz, MeOD) δ159.68, 42.96, 42.18, 32.96, 30.34, 



















3a (commercially available)R= H
R
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(MH+). 3g: 1H NMR (400 MHz, MeOD) δ 4.51 (br s, 1H), 3.03-3.14 (m, 1H), 2.76-
 1.04-1.36 (m, 30H), 0.80 (s, J = 7.0 Hz, 3H). 13C 
0.13, 
 for C19H42N4 m/z 326.34, 
und 327.36 (MH+). 
2.85 (m, 1H), 1.44-1.61 (m, 2H),
NMR (126 MHz, MeOD) δ152.67, 42.17, 40.79, 33.09, 30.79, 30.52, 30.39, 3

















Synthesis of 5. 
To a solution of 4 (930 mg, 1.85 mmol) in anhydrous DMF (8 mL) was added K2CO3 
(768 mg, 5.55 mmol), followed by 3-bromopropanol (194 μL, 2.22 mmol). The 
reaction mixture was stirred at 60 oC for 18 h. The reaction mixture was diluted with 
DCM and the resultant solution was successively washed with water (2X), brine (1X) 
and dried over Na2SO4. After removal of solvent under vacuum, the residue was 
purified by flash column chromatography (hexane:EtOAc = 7:3) to afford the title 
compound 5 as a viscous oil (514 mg, 42%). 1H NMR (400 MHz, CDCl3) δ4.89 (br s, 
3H) , 3.55-3.79 (m, 7H) , 3.09-3.40 (m, 11H) , 1.57-1.77 (m, 8H), 1.44 (br s, 36H). 
13C NMR (126 MHz, CDCl3) δ156.20, 78.60, 58.16, 35.86, 31.81, 27.42, 27.34; MS 






Synthesis of 6. 
To a solution of 5 (500 mg, 0.76 mmol) in anhydrous DCM (20 mL) was added 
pyridinium chlorochromate (PCC; 245 mg, 1.14 mmol) and the solution was stirred at 
ambient temperature for 4.5 h.  After removal of solvent under high vacuum, the 
residue was purified by flash column chromatography (hexane:EtOAc = 3:1) to afford 
the title compound 6 as a viscous oil (349 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 
9.81 (s, 1H) , 3.48-3.56 (m, 2H) , 3.07-3.32 (m, 11H), 2.66-2.77 (m, 2H) , 1.61-1.82 
(m, 5H), 1.40-1.55 (m, 36H). C NMR (126 MHz, CDCl3) δ199.95, 155.09, 154.42, 
78.93, 78.37, 45.80, 45.51, 44.76, 44.15, 43.61, 43.12, 42.64, 42.29, 40.05, 36.28, 
27.87, 27.46, 27.42, 27.39, 27.26, 25.00, 24.55. MS (ESI) calculated for C H N O  



























































General Procedure for the Syntheses of Compounds 7a-g. 
To a solution of 6 (100 mg, 0.15 mmol) in anhydrous EtOH (5 mL) was added 
compound 3a-g (1.3 eq.) followed by catalytic amount of AcOH. The solution was 
refluxed at 85 oC for 2 h. After removal of solvent under high vacuum, the residue 
was purified by flash column chromatography (DCM: MeOH = 9:1) to afford 7a-g as 
yellow viscous oils (70% - 100%).  
7a: yield 80%; H NMR (400 MHz, CDCl3) δ7.32-7.63 (m, 3H) , 3.34-3.62 (m, 3H) , 
2.97-3.33 (m, 11H) , 2.39-2.61 (m, 2H) , 1.56-1.91 (m, 5H), 1.35-1.52 (m, 36H). C 
NMR (126 MHz, CDCl3) δ 156.23, 156.10, 155.86, 155.50, 80.24, 80.00, 79.79, 
79.50, 79.18, 78.98, 65.86, 53.45, 46.81, 46.52, 44.72, 44.21, 43.76, 43.07, 37.71, 
37.38, 28.50, 28.46,28.29, 28.05, 27.98, 27.63, 27.08, 26.03, 25.52, 15.27. MS (ESI) 
calculated for C34H66N8O8:  m/z 714.50, found 715.48 (MH ). 
7b: yield 100%; H NMR (400 MHz, CDCl3) δ7.63 (br s, 1H) , 6.69-7.21 (br m, 1H) , 
2.96-3.56 (m, 16H) , 2.49 (br s, 2H) , 1.55-1.82 (m, 6H) , 1.16-1.54 (m, 52H), 0.80-
0.90 (m, 3H). C NMR (126 MHz, CDCl3) δ156.26, 156.12, 155.53, 154.46, 154.38, 
80.14, 79.95, 79.55, 79.47, 79.24, 79.04, 53.50, 46.57, 46.40, 44.94, 44.25, 42.25, 
7.70, 37.41, 31.75, 28.71, 28.45, 26.66, 25.55, 22.61, 14.10. MS (ESI) calculated for 
42H82N8O8  m/z 826.63, found 827.66 (MH
+). 
c: yield 73%; 1H NMR (400 MHz, CDCl3) δ7.63 (br s, 1H) , 6.69-7.20 (br m, 1H) , 
.99-3.53 (m, 16H) , 2.49 (br s, 2H) , 1.55-1.80 (m, 6H) , 1.14-1.56 (m, 56H), 0.87 (t, 
J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ155.25, 155.21, 155.13, 154.57, 











41.17, 36.69, 36.42, 36.40, 30.84, 27.43, 24.57, 21.64, 14.25, 13.10. MS (ESI) 
, 79.89, 79.54, 79.37, 79.06, 79.02, 65.86, 45.00, 
56.12, 156.06, 155.51, 
m, 6H), 1.15-1.58 (m, 68H), 0.86 (t, J 
calculated for C44H86N8O8  m/z 854.66, found 855.70 (MH
+). 
7d: yield 80%; 1H NMR (400 MHz, CDCl3) δ7.66 (br s, 1H), 6.70-7.22 (br m, 2H), 
3.03-3.53 (m, 16H), 2.50 (br s, 2H), 1.59-1.81 (m, 6H), 1.20-1.54 (m, 60H), 0.87 (t, J 
= 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ156.24, 156.11, 156..06, 155.50, 
155.31, 155.27, 80.15, 80.11, 80.00
44.96, 44.91, 44.83, 44.69, 44.26, 43.79, 42. 23, 37.69, 37.53, 37.42, 29.64, 29.59, 
29.34, 28.69, 28.51, 26.69, 22.68, 15.27, 14.13. MS (ESI) calculated for C46H90N8O8  
m/z 882.69, found 883.72 (MH+). 
7e: yield 75%; 1H NMR (400 MHz, CDCl3) δ7.61 (br s, 1H) , 6.67-7.19 (br m, 2H) , 
2.97-3.55 (m, 16H) , 2.49 (br s, 2H) , 1.55-1.79 (m, 6H) , 1.14-1.56 (m, 64H), 0.85 (t, 
J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ156.25, 1
154.53, 153.98, 153.92, 80.13, 80.07, 79.90, 79.83, 79.53, 79.37, 79.02, 46.85, 46.40, 
45.02, 44.97, 44.94, 44.70, 44.24, 43.78, 42.73, 42.70, 42.29, 37.70, 37.42, 31.91, 
29.69, 29.1, 26.689, 22.68, 14.13. MS (ESI) calculated for C48H94N8O8  m/z 
910.72 ,found 911.75 (MH+). 
7f: yield 71%; 1H NMR (400 MHz, CDCl3) δ7.66 (br s, 1H), 6.67-7.19 (br m, 2H), 
2.97-3.58 (m, 16H) ,2.50 (br s, 2H), 1.58-1.81 (
= 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 155.25, 155.10, 154.52, 148.09, 
147.00, 79.12, 78.83, 78.53, 78.36, 78.03, 52.46, 45.53, 44.50, 43.90, 43.22, 41.20, 
36.69, 36.42, 30.90, 28.68, 28.18, 27.43, 25.68, 24.54, 21.66, 13.11. MS (ESI) 
































General Procedure for the Syntheses of Compounds 8a-g. 
The resultant 7a-g was dissolved in excess dry trifluoroacetic acid (TFA) and stirred 
at r.t. for 30 min. TFA was removed by purging nitrogen and the residue was 
thoroughly washed with dieth
R= H 8a
8bR= C8H17
.57 (m, 70H), 0.89 (t, J 
yl ether to obtain the title compounds as yellow flaky 
7g: yield 70%; 1H NMR (400 MHz, CDCl3) δ 7.61 (br s, 1H), 6.72-7.23 (br m, 2H), 
2.97-3.54 (m, 18H), 2.49 (s, 1H), 1.59-1.78 (br s, 8H), 1.17-1
= 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ169.20, 153.62, 131.75, 126.97, 74.42, 
68.85, 64.98, 64.20, 62.76, 62.59, 62.23, 45.96, 42.33, 40.82, 40.61, 38.94, 32.19, 
30.83, 25.65, 23.32, 14.12, 14.07, 13.96, 8.59. MS (ESI) calculated for C52H102N8O8  




solids 8a-g (~100%). 
8a: 1H NMR (500 MHz, MeOD) δ 7.54 (t, J = 4.1 Hz, 1H), 3.40 (t, J = 7.1 Hz, 2H), 
3.05 (m, 12H), 2.75-2.84 (m, 2H), 2.06-2.23 (m, 4H), 1.78-1.90 (br s, 4H), 1.17-1.36 
(m, 2H). 13C NMR (126 MHz, MeOD) δ 155.70, 147.12, 117.75, 115.43, 46.80, 44.59, 
44.42, 44.39, 43.55, 36.38.  MS (ESI) calculated for C14H34N8  m/z 314.29, found 
158.17 (MH++H+ [doubly-charged species]), 315.33 (MH+). 
8b: 1H NMR (400 MHz, MeOD) δ7.31-7.82 (m, 1H), 3.36-3.43 (m, 15H), 3.06-3.31 
(m, 15H), 2.74-2.85 (m, 2H), 2.03-2.28 (m, 4H), 1.76-1.94 (m, 4H), 1.27-1.48 (m, 
10H), 0.85-0.97 (m, 3H). 13C NMR (126 MHz, MeOD) δ161.86, 161.59, 117.86, 
115.55, 46.81, 43.71, 41.14, 36.41, 31.54, 28.53, 26.28, 23.97, 22.81, 22.70, 22.29, 
13.01. MS (ESI) calculated for C22H50N8  m/z 426.42, found 214.22 (MH
++H+), 
427.42 (MH+). 
8c: 1H NMR (400 MHz, MeOD) δ 7.37-7.67 (m, 1H), 3.35-3.43 (m, 4H), 3.05-3.31 
, 14H), 2.76-2.83 (m, 2H), 2.05-2.25 (m, 4H), 1.75-1.93 (m, 4H), 1.59-1.70 (br m, 
H), 1.23-1.47 (m, 14H), 0.83-1.00 (m, 3H); 13C NMR (126 MHz, MeOD) δ 154.36, 
46.54, 146.49, 146.44, 44.58, 44.43, 44.40,. 43.71, 41.14, 36.40, 31.64, 26.28, 23.98, 
2.81, 22.70, 22.32, 13.03. MS (ESI) calculated for C24H54N8  m/z 454.45, found 
28.23 (MH++H+), 455.45 (MH+). 
, J = 7.1 Hz, 2H), 3.05-
9.34, 29.25, 29.07, 28.57, 28.40, 26.29, 23.97, 22.81, 22.70, 






8d: 1H NMR (400 MHz, MeOD) δ 7.40-7.67 (m, 1H), 3.40 (t
3.31 (m, 14H), 2.74-2.84 (m, 2H), 2.05-2.25 (m, 4H), 1.77-1.90 (br m, 4H), 1.58-1.70 
(m, 2H), 1.24-1.46 (m, 18H), 0.92 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
154.37, 146.62, 146.57, 146.54, 117.47, 115.46, 115.43, 44.59, 44.43, 44.40, 43.71, 
41.13, 36.40, 31.67, 2
22.33, 13.03. MS (ESI) calculated for C26H58N8  m/z 482.48, found 242.25 (MH
++H+), 
483.49 (MH+). 
8e: 1H NMR (400 MHz, MeOD) δ 7.46-7.64 (m, 1H), 3.40 (t, J = 7.1 Hz, 2H), 3.04-
3.30 (m, 14H), 2.73-2.84 (m, 2H) , 2.04-2.25 (m, 4H), 1.78-1.89 (br m, 4H), 1.58-
1.70 (m, 2H), , 1.25-1.42 (m, 22H), 0.92 (t, J = 6.8 Hz, 3H
 55
MeOD) δ 154.37, 146.60, 146.59, 117.74, 115.44, 44.59, 44.43, 44.40,. 43.71, 41.15, 
36.41, 31.67, 28.96, 26.29, 23.97, 22.81, 22.70, 22.33, 13.03. MS (ESI) calculated for 
C28H62N8 m/z 510.51, found 256.31 (MH
++H+), 511.60 (MH+). 
8f: 1H NMR (400 MHz, MeOD) δ 7.51-7.56 (m, 1H), 3.40 (t, J = 7.1 Hz, 2H), 3.05-
3.31 (m, 13H), 2.75-2.84 (m, 2H), 2.05-2.24 (m, 4H), 1.79-1.91 (br m, 4H), 1.58-1.69 
(m, 2H), 1.26-1.46 (m, 26H), 0.92 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
J = 6.7 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 
 
154.36, 146.63, 146.59, 146.55, 117.81, 115.47, 44.60, 44.44, 44.41,. 43.72, 41.15, 
36.41, 31.67, 28.57, 26.29, 23.96, 22.81, 22.70, 13.05, 22.33. MS (ESI) calculated for 
C30H66N8 m/z 538.54, found 270.28 (MH
++H+), 539.56 (MH+). 
8g: 1H NMR (400 MHz, MeOD) δ 7.51 (br s, 1H), 3.40 (t, J = 7.0 Hz, 2H), 3.04-3.30 
(m, 14H), 2.73-2.86 (m, 2H), 2.05-2.24 (m, 4H), 1.77-1.88 (br m, 4H), 1.58-1.69 (m, 
2H), 1.21-1.47 (m, 29H), 0.91 (t, 
154.781, 147.09, 147.03, 45.02, 44.86, 44.84, 44.14, 41.57, 36.83, 32.09, 28.85, 26.71,
24.38, 23.23, 23.12, 22.75, 13.47. MS (ESI) calculated for C32H70N8  m/z 566.574, 









2.6.1.2 Synthesis of analog bearing an N-alkyl substituent on one end and an     





Synthesis of 10. 
Compound 9 (2.4 g, 3.98 mmol) was added to the suspension of NaH (30 eq.) in 
DMF at 0 oC. After the reaction suspension was stirred at 0 oC for 30 min, 1-
H NMR (500 MHz, CDCl3) δ 3.01-3.33 (br 
, 14H), 1.61-1.78 (m, 4H), 1.37-1.54 (m, 40H), 1.25 (s, 27H), 0.88 (t, J = 7.0 Hz, 
H). 13C NMR (126 MHz, CDCl3) δ 156.11, 155.95, 155.48, 79.27, 79.12, 47.10, 
6.80, 46.63, 46.52, 44.90, 44.66, 44.60, 44.18, 43.68, 37.66, 37.29, 31.93, 29.70, 
9.36, 28.45, 26.87, 25.95, 25.89, 25.55, 22.69, 14.13. MS (ESI) calculated for 
46H90N4O8  m/z 826.68, found 849.71 (M+Na
+). 
iodohexadecane (1.68 g, 1.0 eq.) which was dissolved in 5 mL DMF was added to the 
reaction. The mixture was then stirred at r.t. for 24 h.  The reaction solution was 
quenched with 1 M HCl and extracted with DCM (3X). The extracted DCM layers 
were washed with brine (1X) and dried over Na2SO4. After removal of the solvent 
under reduced pressure, the desired compound 10 was isolated at 16% EtOAc/hexane 























Synthesis of 11.: 
o a solution of tert-butyl dimethylsilylchloride (TBDMSCl; 1.2 eq.) and imidazole 
rous DMF was added 3-bromopropanol (1.0 eq.) at 0 oC.121 After   
Cl3) δ 155.44, 79.20, 60.78, 47.08, 
6.83, 46.65, 44.89, 44.62, 44.34, 31.93, 29.70, 29.37, 28.49, 26.88, 25.93, 22.69, 
T
(1.3 eq.) in anhyd
1 h, the reaction mixture was brought to r.t. and stirred for 8 h.  The reaction solution 
was then diluted with ether and the ethereal layer was washed with sat. NaHCO3 
solution (1X) and 10% HCl and dried over Na2SO4. Compound 10 (670 mg, 0.81 
mmol) was added to a suspension of NaH (40 eq.) in DMF at 0 oC.  After the reaction 
suspension was stirred at 0 oC for 30 min, an excess of freshly prepared 3-
bromopropoxy-tert-butyl-dimethylsilane (8.1 mmol) was added to the reaction and 
the solution stirred at r.t. for 20 h. The reaction solution was quenched with 1 M HCl 
and extracted with DCM (3X). The extracted DCM layers were washed with brine 
(1X) and dried over Na2SO4. After removal of the solvent under reduced pressure, the 
desired compound 10 (510 mg, 63%) was isolated at 13% EtOAc/hexane by flash 
column chromatography. 1H NMR (500 MHz, CDCl3) δ3.52-3.64 (br m, 2H),  3.03-
3.25 (br m, 16H), 1.64-1.78 (br m, 6H), 1.41 (s, 40H), 1.14-1.32 (m, 28H), 0.82-0.89 


























Synthesis of 12. 
To a solution of 11 (400 mg, 0.40 mmol) in anhydrous THF (20 mL) was added tetra-
n-butyl-ammonium fluoride (TBAF; 1 M in THF, 174 μL, 0.17 mmol) and the 
solution was stirred at ambient temperature for 2 h .  After removal of solvent under 
high vacuum, the residue was dissolved in 10 mL anhydrous DCM and PCC (130 mg, 
0.60 mmol) was added. The reaction mixture was stirred at r.t. for 4.5 h.  After 
removal of solvent under high vacuum, the residue was purified by flash column 
chromatography (hexane:EtOAc = 3:1) to afford the title compound 12 as a viscous 
oil (260 mg, 74 %). 1H NMR (500 MHz, CDCl3) δ 9.79 (s, 1H), 3.51 (br s, 2H), 3.16 
(br s, 14H), 2.70 (br s, 2H), 1.73 (br s, 5H), 1.45 (br s, 41H), 1.25 (br s, 27H), 0.88 (t, 
J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 200.99, 155.47, 79.93, 79.34, 79.25, 
79.11 47.08, 46.86, 46.84, 46.78, 46.62, 45.80, 44.69, 44.61, 43.63, 43.32, 41.12, 
41.09, 31.93, 30.95, 29.66, 29.37, 28.32, 27.52, 26.88, 25.95, 25.60, 22.69, 14.13. MS 




























Synthesis of 13. 
o a solution of 12 (100 mg, 0.11 mmol) in anhydrous EtOH (5 mL) was added 
ompound 3a (1.3 eq) followed by catalytic amount of AcOH. The solution was 
 for 2 h. After removal of solvent under high vacuum, the residue 
T
c
refluxed at 85 oC
was purified by flash column chromatography (DCM:MeOH = 19:1) to afford the 
title compound 13 as a yellow viscous oil (73%). 1H NMR (500 MHz, CDCl3)  δ 7.48 
(br s, 3H), 3.05-3.32 (br m, 2H), 3.16 (br s, 14H), 2.43-2.56 (br m, 2H), 1.73 (br s, 
4H), 1.45 (br s, 41H), 1.25 (br s, 27H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 155.96, 155.51, 79.97, 79.45, 79.29, 53.44, 47.12, 46.73, 46.61, 44.71, 
43.08, 42.98, 31.92, 31.10, 30.95, 29.69, 29.66, 29.61, 29.42, 29.36, 28.50, 28.47, 
27.59, 27.51, 26.87, 25.97, 25.86, 25.59, 25.55, 22.69, 14.13. MS (ESI) calculated for 

























Synthesis of 14: 
he resulting compound 13 was dissolved in excess dry TFA and stirred at r.t. for 30 
in. Excess solvent was removed by purging nitrogen and the residue was thoroughly 
ashed with diethyl ether to obtain a white solid 14 (~100%). 1H NMR (500 MHz, 
1 (s, 1H), 8.64-8.95 (m, 6H), 7.61-7.96 (br m, 3H), 7.49 (t, J = 4.0, 
 standard rotary evaporators. Flash 
olumn chromatography was carried out using silica gel 635 (60-100 mesh), while 
in-layer chromatography was carried out on silica gel CCM pre-coated aluminum 
eets. All yields reported refer to isolated material judged to be homogenous by 





1H), 3.19-3.27 (m, 2H), 2.83-3.06 (m, 13H), 2.62-2.69 (m, 2H), 1.89-2.01 (br m, 4H), 
1.51-1.69 (br m, 6H), 1.18-1.34 (m, 24H), 0.85 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, DMSO) δ 155.20, 147.44, 118.18, 115.80, 46.71, 46.10, 44.01, 43.86, 43.79, 
42.87, 31.25, 29.00, 28.33, 25.83, 25.37, 22.64, 22.34, 22.32, 22.05, 13.92. MS (ESI) 
calculated for C30H66N8  m/z 538.54, found 270.30 (MH
++H+), 539.54 (MH+). 
 
2.6.2 Materials and Methods 
2.6.2.1 Chemistry: All of the solvents and reagents used were obtained commercially 
and used as such unless noted otherwise. Moisture or air-sensitive reactions were 
conducted under argon atmosphere in oven-dried (120oC) glass apparatus. Solvents 









NF-B inhibition: The inhibition of NF-B (a key transcriptional activator of the 
innate immune system) was quantified using HEK-Blue-4™ cells. Stable expression 
of secreted alkaline phosphatase (sAP) under control of NF-B/AP-1 promoters is 
inducible by LPS, and extracellular sAP in the supernatant is proportional to NF-B 
induction. HEK- Blue-4™ cells were incubated at a density of ~106 cells/ml in a 
volume of 80 µl/well, in 384-well, flat-bottomed, cell culture-treated m crotiter plates 
until confluency was achieved, and subsequently graded concentrations of stimuli 
were added to the cells. sAP was assayed spectrophotometrically using an alkaline 
phosphatase-specific chromogen (present in HEK-detection medium as supp
i
lied by 
e vendor) at 620 nm.  
trols (J774A.1 medium only) were 
cluded in each experiment. Nitrite concentrations were measured by adding 40 l of 
pernatant to equal volumes of Griess reagents (50 µl/well; 0.1% NED solution in 
th
 
Nitric Oxide Assay: Nitric oxide production was measured as total nitrite in murine 
macrophage J774A.1 cells using the Griess assay122 as described in the literature.106 
J774A.1 cells were plated at ~106/ml in a volume of 40 µl/well, in 384-well, flat-
bottomed, cell culture treated microtiter plates and subsequently stimulated with 
10 ng/ml lipopolysaccharide (LPS). Concurrent to LPS stimulation, serially diluted 
concentrations of test compounds were added to the cell medium and left to incubate 
overnight for 16 h. Polymyxin B was used as reference compound in each plate. 




ddH2O and 1% sulfanilamide, 5% phosphoric acid solution in ddH2O) and incubating 
, with graded concentrations of test compounds diluted in 
line for 4 h in a 96-well microtiter plate.123;124 The effect of the compounds on 
for 15 minutes at room temperature in the dark.  Absorbance at 535 nm was measured 
using a Molecular Devices Spectramax M2 multifunction plate reader (Sunnyvale, 
CA). Nitrite concentrations were interpolated from standard curves obtained from 
serially diluted sodium nitrite standards. 
 
Multiplexed cytokine assay ex vivo in human blood: 100 l aliquots of fresh whole 
blood, anticoagulated with heparin, obtained by venipuncture from healthy human 
volunteers with informed consent and as per guidelines approved by the Human 
Subjects Experimentation Committee, was exposed to an equal volume of 100 ng/ml 
of E. coli 0111:B4 LPS
sa
modulating cytokine production was examined using a FACSArray multiplexed flow-
cytometric bead array (CBA) system (Becton-Dickinson-Pharmingen, San Jose, CA). 
The system uses a sandwich ELISA-on-a-bead principle,125;126 and is comprised of 6 
populations of microbeads that are spectrally unique in terms of their intrinsic 
fluorescence emission intensities (detected in the FL3 channel of a standard flow 
cytometer). Each bead population is coated with a distinct capture antibody to detect 
six different cytokines concurrently from biological samples (the human 
inflammation CBA kit includes TNF-, IL-1, IL-6, IL-8, IL-10, and IL-12p70). The 
beads are incubated with 30 l of sample, and the cytokines of interest are first 
captured on the bead. After washing the beads, a mixture of optimally paired second 
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antibodies conjugated to phycoerythrin is added which then forms a fluorescent 
ternary complex with the immobilized cytokine, the intensity (measured in the FL2 
channel) of which is proportional to the cytokine concentration on the bead. The 
assay was performed according to protocols provided by the vendor. Standard curves 
were generated using recombinant cytokines provided in the kit. The data were 
nalyzed in the CBA software suite that is integral to the FACSArray system. a
 
Mouse lethality experiments: Female, outbred, 9- to 11-week-old CF-1 mice 
(Charles River, Wilmington, MA) weighing 22-28 g were used as described 
elsewhere.104;106;113;114 The animals were sensitized to the lethal effects of LPS by D-
galactosamine.125;127;128 The lethal dose causing 100% mortality (LD100) dose for the 
batch of LPS used (E. coli 0111:B4; procured from Sigma) was first determined by 
administering D-galactosamine (800 mg/kg) and LPS (0, 50, 100, 200 ng/mouse) as a 
single injection intraperitoneally (i.p.) in freshly prepared saline to cohorts of five 
animals in a volume of 0.2 mL. Mice received graded doses of compound diluted in 
saline, i.p. in one flank, immediately before a supralethal (200 ng) LPS challenge, 
which was administered as a separate i.p. injection into the other flank. Lethality was 





Toll-like Receptors (TLRs) and TLR2 
 
3.1 Background. 
     Toll-like receptors (TLRs) are pattern recognition receptors present on diverse cell 
types that recognize specific molecular patterns present in molecules that are broadly 
ared by pathogens but distinguishable from host molecules, collectively referred to 
 cells as well as activating natural killer (NK) 
ells [innate immune response], in addition to priming and amplifying T-, and B-cell 
ffector functions133-136 [adaptive immune responses]. Thus, TLR stimuli serve to link 
innate and adaptive immunity134 and can therefore be exploited as powerful adjuvants 
in eliciting both primary and anamnestic  immune responses. TLR1, -2, -4, -5, and -6 
sh
as pathogen-associated molecular patterns (PAMPs).129;130 There are 10 TLRs in the 
human genome; these are trans-membrane proteins with an extracellular domain 
having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1 
receptor (TIR) domain.130 The ligands for these receptors are highly conserved 
microbial molecules such as lipopolysaccharides (LPS) (recognized by TLR4), 
lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single 
stranded RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-
containing DNA (recognized by TLR9), and profilin present on uropathogenic 
bacteria (TLR 11).131;132 The activation of TLRs by their cognate ligands leads to 
production of inflammatory cytokines, and up-regulation of MHC molecules and co-





respond to extracellular stimuli, while TLR3, -7, -8 and -9 respond to 
intracytoplasmic PAM al compartment.130  
LR6 Agonistic Bacterial Lipoteichoic Acid and Lipopeptides. 
       Gram-positive organisms. 









       Figure 16. Structure of lipoteichoic acid (LTA), a constituent of the cell envelope of   
 
     The exoskeleton of the Gram-positive organism, similar to that of Gram-negative 
bacteria, is comprised of underlying peptidoglycan (PGN), a super-sized polymer of 
-1→4-linked N-acetylglucosamine-N-acetylmuramic acid glycan strands that are 
cross-linked by short peptides.137  Unlike in Gram-negative bacteria which bear LPS 
on the outer leaflet of the outer membrane, the external surface of the peptidoglycan 
layer is decorated with lipoteichoic acids (LTA; Figure 16),138 which are anchored in 
the peptidoglycan substratum via a diacylglycerol moiety and bear a surface-exposed, 
polyanionic, 1–3-linked polyglycerophosphate appendage which varies in its subunit 
composition in LTAs from various Gram-positive bacteria; in S. aureus, the repeating 






Figure 17. Structure of MALP-2, the first TLR2 agonistic, immunostimulatory lipopeptide     
entified. The lipopeptide comprises of a diacylthioglycerol unit (yellow) in thioether 
linkage (purple) with cysteine (red). The -amino group of cysteine is acylated (R = 
almitoyl) in triacyl lipopetides. The peptide unit (green) can be variable, and does not 
ppear to be a determinant of immunostimulatory activity. 
   Lipoproteins are found in the bacterial cytoplasmic membrane and are also 












bacteria.  The free amine of the N-terminus of lipoproteins is acylated with a S-(2,3-
diacyloxypropyl)cysteinyl residue which constitutes the immunostim
as shown by studies on synthetic peptides containing the diacylthioglycerol unit (see 
below).139  In contradistinction to enterobacterial LPS which is recognized by Toll-
like receptor-4 (TLR4), PGN,142 LTA,143 lipopeptides,144 as well as some non-
enterobacterial  LPS  signal via TLR2. One of the earliest reports on bacterial 
components other than LPS was the study by Melchers et al.,146 showing that purified 
lipoprotein from the outer membrane of E. coli was a B-lymphocyte mitogen, 
expressing activity in LPS-nonresponder C3H/HeJ mice. Lipoprotein fractions 
isolated from Gram-positive organisms as well as mycoplasmal cultures indicated 
potent macrophage-activating and CTL-inducing properties.  A lipopeptide 
fraction termed mycoplasma associated lipopeptide-2kDa (MA
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subsequently isolated and structurally characterized,141 leading to the identification of 
-(2,3-dihydroxypropyl)cysteine as the structural core of MALP-2.151 Recent 
ructure-activity relationships have sought to examine the stereochemistry, acylation 
attern, and the contributions of the peptide unit.152-155 In contradistinction to Gram-
egative LPS which is recognized by Toll-like receptor-4 (TLR4),136;156-161 the 
ecies were thought to signal via TLR2/TLR1,144;154;162 the recognition of the 








lipopeptides signal via TLR2.144;152;154;162 Although diacyl lipopeptides have been 
reported to be agonists of heterodimers of TLR2/TLR6153;163;164 and triacylated 
sp
lipopeptides by TLR2 has been recently shown to be relatively independent of TLR1 
and TLR6, and are mediated predominantly via TLR2.165;166  
 
3.2.1 Structural basis for the interactions of PAM CSK  with TLR2 an
PAM3CSK4 with TLR2/TLR1: The crystal structures of both PAM2CSK4 and 
PAM CSK with TLR1-TLR2 heterodimers have recently been determined (Figure 
18).167 This not only provides a structural basis for differential recruitment of TLR6 
and TLR1 to heterodimerize with TLR2 by diacyl and triacyl lipopeptides, but also 
allows, for the first time, a rational, structure-based template or the ab initio design 
of novel analogues of TLR2. The N-acyl group of the triacyl PAM3CSK4 interacts 
with a hydrophobic groove in TLR1, driving the formation of an ‘m’ shaped TLR2-
TLR1 dimer (Figure 18), whereas both ester-linked acyl groups of the diacyl 
PAM CSK  are inserted into a hydrophobic pocket in TLR2, rendering the diacyl 
lipopeptide a pure TLR2 ligand.167 The correct stereoisomer is necessary for the 
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appropriate orientation of the ester-linked acyl groups in the hydrophobic pocket of 
TLR2. The external tetralysine peptide unit is almost fully solvent-exposed and does 
not participate in significant interactions with TLR2, which is consistent with our 
















Figure 18. Crystal structure of PAM3CSK4 (shown in spacefill) bound to a heterodimer of  
TLR1 and TLR2 (PDB: 2Z7X). 
 
3.2.2 Effects of the TLR2 agonistic lipopeptides on professional antigen 
presenting cells and effector lymphocytes: The exposure of bone marrow-derived 
dendritic cells of C57/BL6 mice to the lipopeptide FSL-1 has been shown to result in 
a TLR2-dependent upregulation of MHC Class II and CD80/CD86 co-stimulatory 
olecules, with enhanced expression of CD11b and CD11c, associated with the 
production of TNF- and IL-12.168 It is noteworthy that, in this study, whereas LPS 
also induced IL-10 production, FSL-1 only induced a pro-TH1-type cytokine 
168 These results have been independently confirmed in BALB/c mice using 
ALP-2, and extended to show that the lipopeptide also upregulates 
munoproteasome (LMP2, LMP7 and MECL1) activity in a dose-dependent 
anner, suggesting that lipopeptides may indirectly enhance MHC Class I-restricted 
responses by accelerated antigen processing and peptide presentation.169  Importantly, 
the effects of lipopeptides on APC maturation and antigen presentation have also 
een demonstrated in human DCs.170 
   MALP-2 directly stimulates murine B lymphocytes without accessory APC help in 
 TLR2- and dose-dependent fashion. The expansion in the resting CD19+ population 
as accompanied by upregulation of both MHC Class I and II molecules, as well as 
D25 (IL2R), CD40, CD80 and CD86.171 Triacyl PAM3CSK4 has been shown to 
duce IL-6 production in human tonsillar B cells.172 In addition, PAM2CSK4 and 
 IgG-secreting plasma cells,173 indicating a functional association between BCR 












MALP-2 induce isotypic switching and differentiation of naïve human B lymphocytes 
to
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dramatically enhance MHC Class I-restricted CTL proliferation to an 
immunodominant influenza peptide Mx58-66 in a human autologous DC/CD8
+ T cell 
co-culture model.174 The peptide-specific CTLs (assessed by tetramer staining) were 
also found to be strong producers of IFN-. Lipopeptide-primed DCs also stimulated 
the proliferation of allogeneic naïve CD8+ CTLs.174 Intranasal immunization of mice 
with influenza-specific peptide resulted in greatly enhanced numbers of IFN--
secreting CD8+ CTLs when lipopeptides were used as adjuvants.175 Similarly, MALP-
2 induces robust, long-lived CTL responses against HIV-1 Tat protein.176;177  
     These results collectively indicate that the adjuvanticity of the lipopeptides 
encompasses a strong CTL response. Reports as early as 1997 indicated that 
PAM3CSK4 markedly enhanced the humoral response to haptens conjugated to poly-
L-lysine; adjuvanticity was also observed by these authors for the lipopeptide-TH1 
cell epitope conjugates in in vitro immunization protocols.178 It was subsequently 
shown using human lymphocytes ex vivo, that PAM3CSK4-dependent CD4
+ T cell 
differentiation and proliferation required professional APC, and that naïve CD4+ T 
cell differentiation progressed with faster kinetics in the presence of the adjuvant. The 
lipopeptide enhanced the frequency of in vitro expanded TH cells specific for tetanus 
toxoid and hepatitis B surface antigen peptides, with the majority of the expanded 
CD3+/CD4+ cells being positive for IFN-.179 A recent study indicates that the 
lipopeptides lower the threshold for TH1 responses by TLR2-dependent secretion of 
IL-12p70 by DC.180 
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Chapter 4 
Structure-Activity Relationships in TLR2-Agonistic Diacylthioglyceryl 
Lipopeptides 
 
4.1 Introduction and Rationale. 
     The link between immune stimulation resulting from acute infection and the 
resolution of tumors has long been recognized,181 and the phenomenon of infection-
related "spontaneous regression" of cancer has been documented throughout history, 
rgence of interest in the immunotherapy of neoplastic states.193-
195 
beginning as early as 2600 B.C..182;183 The foundations of modern immunotherapy for 
cancer were laid in 1891 by William B. Coley, who injected live streptococcal 
organisms into a long-bone sarcoma lesion and observed shrinkage of the tumor.184  
More than a century has elapsed since Coley’s empirical findings were first reported, 
but the active principle(s) in Coley’s toxin remain undetermined. This long lag-period 
is perhaps not altogether surprising because the recognition of innate immune system 
is, in itself, recent,185-187 and our understanding of the structure and function of the 
family of Toll-like receptors (TLRs)159;188 that recognize “pathogen-associated 
molecular patterns (PAMPs)”,189 and the effector mechanisms that mediate innate 
immune responses129;190;191 are yet nascent. Nonetheless, there exists considerable 
potential in harnessing innate immune responses in a wide range of disease states, 
notably cancer, as evidenced by the number of TLR agonists already in clinical 
trials,192 and the resu
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     In comparing the various constitu Gram-positive cell, we have found 
lipope ity 
in animal models.196 In murine ce 4 (S-[2,3-bis(palmitoyloxy)-(2RS)-
propyl]-R-cysteinyl-S-seryl-S-lysyl-S-lysyl- S-lysine), a commercially-
ptide (Figure 19), was equipotent in its NF-B 
2
se 
I/Phase II clinical trial197  on a single, intraoperative 20-30 g intratumoral injection 
ents of the 
ptides to be extremely potent TLR2 agonists, and yet without apparent toxic
lls, PAM2CSK
S-lysyl-
available, synthetic model lipope
inducing activity relative to LPS, but elicited much lower proinflammatory cytokines, 
while both LPS and the lipopeptide potently induced the secretion of a similar pattern 
of chemokines suggestive of the engagement of downstream TRIF pathways.196 
Furthermore, we have found that while LPS, as expected, elicited a robust fever 
response in rabbits at a dose of 200 ng/kg, a 200 g/kg dose (1000X) of the 
lipopeptide (PAM2CSK4) was without any discernible pyrogenic or other apparent 
acute toxic effect (Figure 20). In the following assay of induction of cytokines in 
human blood (The most representative data [TNF- IL-L-6] was shown here, 
Figure 21), it was proved  that PAM2CSK4 might be not proinflammatory. Shown 
from the assay, PAM CSK4 did not trigger any release of cytokines while LPS 
showed a strong proinflammatory effect. However, PAM2CSK4 does stimulate the 
production of nitric oxide (NO) in murine M and the phosphorylation of p38MAPK 
in human blood, both of which serve as indicators for immunostimulation (Figure 
22). It was also discovered that PAM2CSK4, like LPS, stimulates natural killer (NK) 
cells (Figure 23). These observations all suggest that the lipopeptides may be 
remarkably potent, yet nontoxic immunotherapeutic agents. Indeed, in a Pha
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of MALP-2141 (a diacyl lipopeptide similar in its core structure to PAM2CSK4) in 
patients with inoperable carcinoma of the pancreas, the lipopeptide was well-tolerated 
and proved efficacious in prolonging survival.197 
     Considerable structure-activity relationships dictating TLR2 binding and 
subsequent stimulation of innate immune responses have been documented for a 
range of synthetic lipopeptides. The minimal structure for biological activity is the 
Cys-Ser lipodipeptide198 with the lipoaminoacid Cys-OH derivative being almost 
inactive;199 the remainder of the peptidic unit appears, in large part, not to be critical  
for activity since a variety of analogues of different lengths with different amino acid 
sequences were found to be equipotent.198;200-202 The (R)-configuration at the 
asymmetric glyceryl carbon confers maximum activity,152;203 and the threshold of the 
acyl chain length of the two ester-bound fatty acids is 8 carbons, with shorter acyl 
analogues being inactive.144  It should be pointed out, however, that the majority of 
earlier SAR studies had been performed with murine cells, many even before the 
TLRs had been discovered, and it is now clear that significant species-specific 
differences exist between human and murine TLR responses144;204 as a consequence 
of subtle structural differences in the ligand binding pocket within TLR2.167 
Furthermore, the recent high-resolution crystal structure of lipopeptides complexed to 
human- as well as murine-derived TLR1/TLR2 heterodimers  raises additional 
questions since the binding site in TLR2 is highly unusual, being located in the 
convex region formed at the border of the central and C-terminal domains with the 
peptidic unit interacting with interfacial residues at the neck region of the binding 
167
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pocket.167 It was of interest to examine whether the chirality of the highly conserved 
Cys residue (L-Cys versus D-Cys) and the thioether bridge connecting the 
diacylglycerol unit to the peptide chain are critical determinants of activity, and if the 
 
thioether could be bioisosterically substituted by an ether linkage. The importance of 
the ester-linked palmitoyl groups on the thioglycerol backbone is also not 
documented, and the effect of replacing them with amide-linked acyl groups 
remained to be explored. The geometry of the Cys-Ser dipeptide unit also appears to 
be crucial, in that there are key interactions with conserved Tyr316 and Pro315
residues at the neck of the binding pocket (Figure 19) in the crystal structure.167 I 
wished to examine the effect of inverting the stereocenters of both residues in the 
dipeptide unit. It is also to be noted that the carboxylic acid of Cys is in amide linkage 
with the amine of serine (Figure 19), and I wished to test whether inversion of the 
orientation of Ser, resulting by the coupling the carboxyl group of serine to the amino 
































































igure 19. Top: The structure of PAM2CSK4. R is palmitoyl in PAM3CSK4. Bottom: The 
rystal structure of PAM3CSK4 bound to a heterodimer of human-derived TLR2 and 
LR1 (PDB code: 2z80). The acyl groups are shown in emphasized sticks with van der 
aals surfaces represented by dots. The Cys-Ser dipeptide in shown as dark spheres 
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       Figure 21. Induction of cytokine release by LPS and PAM2CSK4 in human blood. 
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Figure 22. Induction of NO and phosphorylation of p38MAPK with LPS and PAM2CSK



























































































p38MAPK Phosphorylation in Human Blood  













igure 23. Expansion of CD25+/CD56+ double-positive natural killer (NK) cells 
population upon stimulation of human whole blood with 1 g/ml LPS or PAM2CSK4. 
.2 Syntheses and Evaluation of Cysteamine Analogs (6a-b) and Cysteamine-
inverse serine analogs (8a-b) 
 Much of the previous work in the literature concerning the structure-activity 
murine TLR2, and in an effort to confirm 
the minimal part-structure of the lipopeptide that was TLR-agonistic on human TLR2, 
irst targeted the stereoselective syntheses of 1,2-dipalmitoyl (R)- and -(S)-3-(2-
minoethylthio)propanediol (6a and 6b, Scheme 1) starting from the corresponding 
nantiopure 1,2-isopropylideneglycerol. The (R)-cysteamine lipo-amino acid 6a was 
 























completely inactive. Coupling L-serine to the free amine of the cysteamine resulted in 
the lipodipep d 8b; similar to the cysteam ly 8a was active 
with an IC50 of 1.2 M; it is to be noted that in these latter compounds, the dipeptide 
unit is inverted since, unlike in the naturally occurring as well as in synthetic 



































Reagents an conditions: a: p-TsCl, pyr, DCM, 0 oC-r.t., 8 h;
b: N-Boc-2-aminoethanethiol, NaH, DMF, 0 oC-r.t., 8 h;
c: 70% AcOH, r.t., 12 h;
d: C15H31COCl, pyr, DMAP, DCM, 0 oC-r.t., 10 h;
e: TFA, r.t., 30 min; f: Boc-L-Serine-OH, EDCI, EDIPA, DMAP, DCM, 0 oC-r.t., 8 h;




























































































4.3 Syntheses and Evaluation of PAM2C-OMe (11), PAM2CS-OH (14a) and 
PAM2CS-OMe (14b-d) analogs. 
   The L-cysteine-containing lipo-amino acid , compound 11 (Scheme 2) is also 
eakly TLR2-agonistic, which is in contradistinction to the virtually absent activity 
n murine cells described earlier.199  The results emphasize differences in ligand 
ecificity between murine and human TLR2. The difference in activity between the 
- and S-isomers which was consistent with previous SAR results,152;203 served to 
cus our subsequent  SAR in which we elected to examine only the R-
iacylthioglycerol analogues.  
   The PAM2Cys-Ser compounds of the 14 series comprising of combination of L- or 
-amino acids at either position, and with the carboxyl terminus as either the 
arboxylic acid or the methyl ester (Scheme 2) were all highly active with the IC50 
alues in the mid-picomolar range (Figure 24), signifying that the stereochemistry of 
e dipeptide unit is non-critical as long as the orientation of the amide bond is in the 
orrect configuration as discussed earlier. These results are constant with the crystal 
ructure of PAM2CSK4 complexed with TLR2, in which the carbonyl Cys-Ser amide 
ond forms H-bonding with Pro315 and the NH of the amide interacts with Y326, but 
e side-chains of the dipeptide unit show no significant van der Waals interactions 
ithin the binding pocket.167 The relative unimportance of the side-chains of the 
ipeptide core are also in agreement with observations that in naturally-occurring 
popeptides, the second amino acid is far less conserved, and can be replaced by 






















steric interactions within the narrow neck region of the binding pocket167 are not 
promised. While the PAM2CS methylester com compounds are indeed highly active, 
 of O-bridged (21a-b) and Ether (28) Analogs. 
they are about a fifth as potent as the reference PAM2CSK4 lipopeptide. We have 
found that, as with other amphipathic compounds that we have recently 
characterized,205 the apparent differences in potencies are related, at least in part, to 
the substantially higher binding of the more hydrophobic PAM2CS analogues to 
albumin present in cell culture media, details of which will be published elsewhere. 
 
4.4 Syntheses and Evaluation
     It was of particular interest to examine the role of the thioether bridge between the 
diacyl and dipeptide units. O-alkylation of S-1,2-isopropylideneglycerol with racemic 
ethyl 2,3-epoxypropanoate yielded the key intermediate 15, from which the ether-
bridged compounds were obtained (21a and 21b, Scheme 3) in which two of the 
three stereocenters were held fixed. The activity of 21a (lipopeptide terminating with 
L-Ser) was about eight orders of magnitude lower (IC50: 1.2 mM) than that of 
PAM2CSK4 while 21b (D-Ser) was inactive at the highest concentration tested (10 
mM). While these results are indicative of the absolute requirement of the thioether 
linkage, we do not yet understand why the stereochemistry of the terminal Ser residue 
manifests in differential activity only in the ether-linked (21a, 21b), but not in the 
















































































ys-L-Ser 14a: X=H; 14b : X=Me







Reagen toluene, 90oC, 2 h;
Me, TEA, DMF, 85oC,4 h;
c: i) 70% AcOH, r.t.,24h; ii) C15H31COCl, pyr, DMAP, DCM, 0
oC- r.t., 12h;
iii)TFA, r.t., 30 min.
d: i) LiOH, THF/H2O, r.t.; ii)H-L-Ser(OtBu)-Ot-BuHCl or H-L-Ser(OtBu)-OMeHCl
or H-D-Ser(OtBu)-OMeHCl, EDCI, EDIPA, DMAP, DCM, 0oC-r.t., 8h;
e: i) 70%AcOH, r.t.,12h; ii) C15H31COCl, pyr, DMAP, DCM, 0
oC-r.t., 10h;











ts and conditions: a: PPh3, I2, imidazole,








































































































Reagents nd conditions: a: Ethyl 2,3-epoxypropanoate, BF3OEt2, DCM, r.t., 5 h;
b: p-TsCl, TEA, DCM, 0C-r.t., 3 h;
c: NaN3, DMF, r.t., 12 h;
d: i) PPh3, H2O, THF, reflux, 6 h; ii) Boc2O, TEA, DCM, r.t., 12 h;
e: i) LiOH, THF/H2O, r.t., 12 h; ii) H-L-Ser(tBu)-OMeHCl or H-D-Ser(tBu)-OMeHCl,
EDCI, EDIPA, DMAP, DCM, 0C-r.t., 12 h;
f: i) 70% AcOH, r.t., 12 h; ii) C15H31COCl, pyr, DMAP, DCM, 0C-r.t., 12 h;





















































































Reagents and conditions: a: BnBr, NaH, DMF, 0 oC- r.t., 8 h;
b: i) 70% AcOH, r.t., 12 h; ii) C16H33I, NaH, DMF, 0
oC- r.t., 8 h;
c: i) Pd/C, H2; ii) TsCl, pyr, DMAP, DCM, 70
oC, 12 h;
d: I2, KI, DMF, 80
oC, 24 h;
e: Boc-L-Cys-OMe, TEA, DMF, 80 oC, 2 h;
f: i) LiOH, THF/H2O, r.t., 4h; ii) H-L-Ser(tBu)-OMeHCl EDCI, EDIPA, DMAP,
DCM, 0 oC-r.t., 8 h;
























 [67 pM] 
 6a [1 M]
 6b [Inactive]








 14a [384 pM]
 14b [208 pM]
 14c [405 pM]
 14d [462 pM]
 8b [Inactive]





































TLR2 agonistic activities of the lipopeptide analogues. HEK293 cells stably 
ansfected with a TLR2-NF-B-SEAP reporter gene was used in a 384 well format. Data 





















     We next tested whether the ester-linked palmitoyl groups could be replaced with 
otentially hydrolytically more stable ether and amide linkages without 
ompromising activity. Synthesis of analogue 28 with the ether-linked C16 
hydrocarbon appendages could not be obtained by direct O-alkylation of an advanced 
ediate such as the deprotected species from series 12 under a variety of 
onditions. This necessitated the installation of the ether-linked C16 groups on the 
lycerol backbone (23) first, followed by transformation of the free hydroxyl to the 
do intermediate (25), and  subsequent S-alkylation with cysteine. We found that the 
ther analogue 28 was entirely inactive (Figure 25).  
4.5 Syntheses and Evaluation of Monoamide (37) and Diamide (45) Analogs. 
     We next investigated the bioisoteric replacement of one (internal, secondary 
lcohol-derived; Scheme 5) ester as well as both the esters (Scheme 6) with amide-
nked hydrocarbon chains. Synthesis of the monoamide analogue 37 proceeded 
moothly starting from D-Ser-OMe (29). The diamide analogue, 45, however, was 
ore problematic to synthesize. Acetonide deprotection of the monoamide precursor 
5, followed by attempts at converting the free hydroxyl group to the amine via an 
azide intermediate was unsuccessful. The strategy of first N-acylating (R)-methyl 2,3-
diaminopropanoate with palmitoyl chloride, and then converting the ester to the iodo 
ia the alcohol as described in Scheme 5 was also not fruitful because of unexpected 















difficulty in the conversion of the alcohol to the iodo group. This is probably due 
either to steric bulk of the long-chain amides or to an interna
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free alcohol and one of the amide groups. We therefore resorted to first installing the 
iodo on a N, N’-di-Boc-protected 2,3-diaminopropane-1-ol, followed by S-alkylation 
with N-Troc-L-Cys-OMe (Scheme 6), affording the required orthogonality of the 
protecting groups. The amines on the diaminopropane-thiol fragment of compound 41 
were then acylated with hexadecanoic acid. Next, the base-labile N-Troc protecting 
group on the cysteine unit had to be converted to the N-Boc derivative in order to 
carry out subsequent base-catalyzed de-esterfication step. Coupling of the terminal 
Ser residue proceeded smoothly. 
     The monoamide derivative 37 was found to be partially active (IC50: 48 nM, 
igure 25), although weaker by about three orders of magnitude compared to the 
tive. 
F
reference lipopeptide PAM2CSK4. The diamide derivative 45 was completely inac
The progressive loss of activity from the monoamide to the diamide analogue 
suggests that both ester groups are important for maximal TLR2-stimulatory activity, 
although this is yet to be formally tested by synthesizing the regioisomer of 37 with 
the amide group replacing the external (primary alcohol-derived) ester group. 
     We were also keen to test the possibility that some of the inactive compounds 
could perhaps behave as TLR2 antagonists, particularly with 8a and 8b, since we had 
designed these compounds with inverted cysteamine-serine amide bonds in the hope 
that this would be the case. It could be noted in this context that TLR2-mediated 
immunopathology has been implicated in a number of inflammatory bowel 
diseases,206-209and the only reported TLR2 receptor antagonists are rather weak 



















































Reagents and conditions: a: C H COCl, aq.NaHCO , EtOAc, r.t.,1h;
c: LiBH4, THF, 0°C(3h) - r.t.(6h);
e: Boc-L- or -D-Cys-OMe, TEA, DMF, 80 C, 2 h;
DMAP,
- r
g: i) 70%AcOH, r.t.,12h; ii) C15H31COCl, pyr, DMAP, DCM, 0
oC-r.t., 10h;
h: TFA, r.t., 30 min.
15 31 3
b: 2,2-DMP, PPTS, toluene, 90 °C, 22h;
d: PPh3, I2, toluene, 90
oC, 2 h;
o
f: i) Ba(OH)2, CH3CN/H2O, 60
oC, 1h; ii)H-L-Ser(tBu)-OMe · HCl, EDCI, EDIPA,



















37 and 45 were all inactive as TLR2 receptor antagonists, the negative results add to 
the SAR data in that they demonstrate that these compounds do not bind to and 


















































































































conditions: a: i) (Boc)2O, TEA, DCM, r.t., 2 h; ii) MeOH, EDCI, HOBt, TEA, DMAP, DCM, 10h;
b: NaBH4, MeOH, THF, reflux, 4h;
c: I2, PPh3, imidazole, DCM, 0
oC-rt, 2h;
d: N-Troc-L-cysteine methyl ester, TEA, DMF, 85 oC, 2h;
e: i) TFA, r.t., 30 min; ii) C15H31COOH, EDCI, HOBt, TEA, DMAP, DMF, 60 oC, 10h;
f: i) Zn dust, AcOH, H2O, THF, r.t., 1h; ii) (Boc)2O, TEA, DCM, r.t., 1h;
g: i) Ba(OH)2, THF/H2O, 60
oC, 1h; ii)L-Ser(t-Bu)-OMe  HCl, EDCI, HOBt, EDIPA, DMAP,
DMF, 60oC, 10h;





























































 37  [48 nM]














           Figure 25 TLR2 agonistic activities of the lipopeptide analogues (continued ). 
 
     In addition to the lipopeptides being potentially useful as immunotherapeutic 
agents for cancer, they also display potent adjuvant properties. Lipopeptides greatly 
enhance MHC Class I-restricted CTL proliferation to an immunodominant influenza 
peptide Mx58-66 in a human autologous DC/CD8
+ T cell co-culture model.174 
Lipopeptide-primed dendritic cells also stimulate the proliferation of allogeneic naïve 
CD8+ CTLs,174 and immunization of mice with influenza-specific peptide results in 
greatly enhanced numbers of interferon--secreting CD8+ CTLs when lipopeptides 
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were used as adjuvants.175 Similarly, MALP-2 induces robust, long-lived CTL 
responses against HIV-1 Tat protein.176;177 The synthetic methods that we have 
developed are easily scalable, and the availability of a free amino group in PAM2CS 
should allow the facile introduction of electrophilic labels such as isothiocyanate for 
covalent coupling to vaccine antigens. Differential protein binding should also allow 
considerable control of pharmacokinetic properties. These are currently being 
stigated. 
.6 Conclusions. 
   The SAR exploration of the diacylthioglyceryl lipopeptide compounds revealed 
e essential role of the dipeptide unit as well as the thio-linkage. The ester linkages 
n the diacyl hydrocarbon chains were also among the determinants for TLR2 
gonistic activity, with replacement with ether or amide bonds leading to a dramatic 
e 








loss in activity. The analog with one ester-linkage (internal) substituted by an amid
li
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4.7 Experimental Data. 
4.7.1 Experimental Procedures 











Syntheses of Compounds 2a ((R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-
methylbenzenesulfonate and 2b ((S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-
methylbenzenesulfonate). 
O-tosylation of (S)-(+)- [1a] and (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol 
[1b].To enantiopure (S)-(+)- or (R)-(−)-2,2-dimethyl-1,3-dioxolane-4-methano1 
(compounds 1a and 1b, respectively, 1.0 g, 7.57 mmol, Sigma-Aldrich, Inc., St. Louis, 
MO) dissolved in anhydrous DCM (30 mL) and cooled to 0 C was added pyridine 
(1.22 mL, 15.14 mmol), followed by p-toluenesulfonyl chloride (p-TsCl; 2.89 g, 
22.70 mmol).  The reaction solution was brought to r.t. and stirred for 8 h.  After 
removal of solvent under vacuum, the residue was purified by flash column 
chromatography (hexane:EtOAc = 49:1) to afford the literature compounds 2a (R) 















Syntheses of Compounds 3a ((R)-tert-butyl 2-((2,2-dimethyl-1,3-dioxolan-4-
yl)methylthio) ethylcarbamate) and 3b ((S)-tert-butyl 2-((2,2-dimethyl-1,3-
dioxolan-4-yl)methylthio) ethylcarbamate). 
To a solution of 2a or 2b (800 mg, 2.80 mmol) in anhydrous DMF (15 mL) cooled to 
on solution was then brought to r.t. and stirred for 8 h. 
, 3H). 13C NMR (126 MHz, CDCl3) δ 155.78, 
09.67, 79.48, 75.58, 68.82, 39.79, 33.01, 28.40, 26.90, 25.55. MS (ESI) calculated 
r C13H25NO4S, m/z 291.15, found 292.16 (M+H)
+ and 314.14 (M+Na) +. 
0 oC was added sodium hydride (NaH; 101 mg, 4.19 mmol). After stirring for 30 min 
at 0 oC, N-Boc-cysteamine (N-Boc-2-aminoethanethiol; 595 mg, 3.36 mmol) was 
added dropwise. The reacti
After quenching unreacted NaH with 1 M HCl, the solvent was removed under 
reduced pressure, and the residue was dissolved in EtOAc and washed with water.  
The water layer was extracted thrice with EtOAc. The combined organic layers were 
washed with brine and dried over Na2SO4. After removal of solvent under reduced 
pressure, the residue was purified by flash column chromatography (hexane:EtOAc = 
5:1) to afford the title compounds 3a and 3b as colorless oils (90-94%).  
3a:  1H NMR (400 MHz, CDCl3) δ 4.98 (d, J = 27.4, 1H), 4.22 (p, J = 6.2, 1H), 4.07 
(dd, J = 6.1, 8.3, 1H), 3.67 (dd, J = 6.4, 8.3, 1H), 3.35 (m, 2H), 2.78 – 2.58 (m, 4H), 




3b: 1H NMR (400 MHz, CDCl3) δ 4.92 (s, 1H), 4.23 (p, J = 6.2, 1H), 4.12 – 4.04 (m, 
H), 3.68 (dd, J = 6.4, 8.3, 1H), 3.31 (m, 2H), 2.79 – 2.58 (m, 4H), 1.43 (s, 9H), 1.41 
, J = 0.4, 3H), 1.34 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 155.78, 109.65, 79.45, 
75.57, 68.81, 39.80, 24.95, 32.98, 28.40, 26.89, 25.55. MS (ESI) calculated for 






Syntheses of Compounds 4a ((R)-tert-butyl 2-(2,3-dihydroxypropylthio)-
ethylcarbamate) and 4b ((S)-tert-butyl 2-(2,3-dihydroxypropylthio)- 
ethylcarbamate). 
Acetonide deprotection of compounds 3a and 3b (900 mg, 3.09 mmol) was achieved 
by adding 70% acetic acid (AcOH:H O = 7:3) and stirring at r.t. for 12 h.  After 
removal of solvent under vacuum, the reaction residue was dissolved in EtOAc, and 
washed with sat. NaHCO  solution. The aqueous layer was extracted thrice with 
EtOAc. The combined EtOAc layers were washed with brine and dried over Na SO . 
After removal of solvent under vacuum, the residue was purified by flash column 















4a: 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.3, 1H), 7.34 (d, J = 8.0, 1H), 4.93 (s, 
1H), 3.85 – 3.75 (m, 1H), 3.70 (dt, J = 5.2, 10.3, 1H), 3.55 (dd, J = 5.9, 11.3, 1H), 
3.31 (d, J = 5.3, 2H), 2.77 – 2.57 (m, 4H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) 
δ 156.20, 79.80, 70.40, 65.26, 39.85, 35.53, 32.96, 28.40. MS (ESI) calculated for 
C10H21NO4S, m/z 251.12, found 252.13 (M+H)
 + and 274.11 (M+Na) +. 
4b: 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 6.98 (s, 1H), 4.87 (s, 1H), 3.79 (ddd, 
 = 4.2, 6.9, 12.0, 1H), 3.75 – 3.68 (m, 1H), 3.55 (dt, J = 5.6, 11.3, 1H), 3.32 (d, J = 
.9, 2H), 2.78 – 2.55 (m, 4H), 1.43 (s, 9H). MS (ESI) calculated for C10H21NO4S, m/z 
51.34, found 252.13 (M+H) + and 274.12 (M+Na) +. 
yl chloride (876 mg, 3.19 mmol) was then added dropwise  and the reaction 









Syntheses of Compounds 5a ((R)-3-(2-(tert-
butoxycarbonylamino)ethylthio)propane-1,2-diyl dipalmitate) and 5b ((S)-3-(2-
(tert-butoxycarbonylamino)ethylthio)propane-1,2-diyl dipalmitate). 
O-palmitoylation of compounds 5a and 5b. To a solution of compound 4a and 4b 
(200 mg, 0.80 mmol) in anhydrous DCM (8 mL) at 0 oC were added pyridine (385 












mixture was sequentially washed with water, sat. NaHCO3, brine, and then dried over 
Na2SO4. After removal of solvent under vacuum, the residue was purified by flash 
column chromatography (hexane:EtOAc = 8:1) to afford the title compounds 5a and 
5b as white solids (90-92%). 
5a: 1H NMR (400 MHz, CDCl3) δ 5.12 (m, 1H), 4.88 (s, 1H), 4.34 (dd, J = 3.5, 11.9, 
 29.66, 29.61, 29.52, 29.46, 
9.38, 29.31, 29.26, 29.15, 29.13, 29.09, 28.39, 24.91, 24.74, 22.71, 14.15. MS (ESI) 
alculated for C42H81NO6S, m/z 727.58, found 728.59 (M+H)
 + and 750.57 (M+Na) +. 
b: 1H NMR (400 MHz, CDCl3) δ 5.12 (m, 1H), 4.88 (s, 1H), 4.34 (dd, J = 3.5, 11.9, 
H), 4.15 (dd, J = 6.0, 11.9, 1H), 3.30 (d, J = 6.1, 2H), 2.68 (dd, J = 6.4, 11.5, 4H), 
.34 – 2.25 (m, 4H), 1.64 – 1.56 (m, 4H), 1.42 (s, 9H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 
z 727.58, found 728.59 (M+H) + and 
1H), 4.15 (dd, J = 6.0, 11.9, 1H), 3.30 (d, J = 6.1, 2H), 2.68 (dd, J = 6.5, 11.5, 4H), 
2.38 – 2.24 (m, 4H), 1.62 – 1.54 (m, 4H), 1.42 (s, 9H), 1.25 (d, J = 10.6, 48H), 0.86 
(t, J = 6.9, 6H). 13C NMR (126 MHz, CDCl3) δ 173.42, 173.16, 155.77, 79.50, 70.30, 






6H). MS (ESI) calculated for C42H81NO6S, m/













General procedure for N-Boc deprotection: Syntheses of Compounds 6a ((R)-3-
(2-aminoethylthio)propane-1,2-diyl dipalmitate) and 6b ((S)-3-(2-
aminoethylthio)propane-1,2-diyl dipalmitate). 








), 1.50 (d, J = 6.2, 4H), 1.23 (s, 48H), 0.84 (t, J = 6.8, 6H). MS 




min. TFA was removed by purging nitrogen and the residue was thoroughly washed
with diethyl ether to obtain the title compounds as flaky white solids (98-100%). 
6a: 1H NMR (400 MHz, DMSO) δ 7.83 (s, 1H), 5.18 – 5.06 (m, 1H), 4.30 (dd, J 
2.7, 11.9, 1H), 4.10 (dd, J = 7.2, 12.0, 1H), 2.99 (t, J = 7.2, 2H), 2.90 – 2.65 (m, 4H),
2.32 – 2.14 (m, 4H), 1.58 – 1.42 (m, 4H), 1.23 (s, 48H), 0.84 (t, J = 6.8, 6H). 13
NMR (126 MHz, DMSO) δ 172.47, 172.29, 69.64, 63.47, 33.62, 33.53, 33.37, 31.29, 
30.87, 29.06, 29.03, 29.01, 28.93, 28.75, 28.71, 28.50, 28.42, 28.38, 24.47, 24.38, 
22.08, 13.91. MS (ESI) calculated for C37H73NO4S, m/z 627.53, found 628.51
(M+H)+. 
6b: 1H NMR (400 MHz, DMSO) δ 7.80 (s, 1H), 5.16 – 5.05 (m, 1H), 4.30 (dd, J =
2.8, 11.9, 1H), 4.10 (dd, J = 7.1, 12.0, 1H), 2.99 (t, J = 7.1, 2H), 2.87 – 2.65 (m, 4H
























ied by flash column chromatography (hexane:EtOAc = 3:2) to afford the 
58 (s, 4H), 1.44 
, 9H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 172.30, 
72.13, 170.33, 154.96, 79.32, 69.11, 62.38, 61.73, 53.57, 37.04, 33.11, 32.90, 31.01, 
0.72, 28.50, 28.46, 28.44, 28.29, 28.16, 28.09, 27.92, 27.10, 23.68, 21.49, 12.92. MS 
SI) calculated for C45H86N2O8S, m/z 814.61, found 837.56 (M+Na)
 +. 
diazatetradecane-13,14-diyl dipalmitate). 
The terminal L-serine of the dipeptide unit was appended to 6a and 6b by 
conventional solution phase coupling procedures. To 6a and 6b (200 mg, 0.27 mm
in anhydrous DCM (8 mL) at 0 oC  were added Boc-L-Ser-OH (Bachem Americas, 
Inc., Torrance, CA, 83 mg, 0.40 mmol), (3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDCI; 103 mg, 0.54 mmol), N, N-
diisopropylethylamine (EDIPA; 53.4 L, 0.32 mmol), and a catalytic amount of 
DMAP. The reaction mixture was stirred at 0 oC for 30 min, and then brought to r.t., 
and stirred for an additional 8 h.  After removal of solvent under vacuum, the residue 
was purif
title compounds 7a or 7b as white solids (75-80%). 
7a: 1H NMR (400 MHz, CDCl3) δ 6.92 (s, 1H), 5.54 (s, 1H), 5.11 (dt, J = 5.0, 9.8, 
1H), 4.36 (dd, J = 3.3, 11.9, 1H), 4.16 – 4.04 (m, 3H), 3.64 (s, 1H), 3.56 – 3.37 (m, 






7b: 1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 5.53 (s, 1H), 5.12 (qd, J = 3.4
1H), 4.35 (dd, J = 3.4, 11.9, 1H), 4.16 – 4.03 (m, 3H), 3.64 (s, 1H), 3.57 – 3
2H), 2.91 (s, 1H), 2.78 – 2.61 (m, 4H), 2.29 (td, J = 4.1, 7.6, 4H), 1.60 (s,
(s, 9H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H)
, 6.5, 
.34 (m, 
 4H), 1.44 
. MS (ESI) calculated for C45H86N2O8S, 
 earlier in the general procedure 
2.27, 166.69, 
69.88, 63.45, 60.27, 54.35, 38.52, 33.55, 33.37, 31.28, 31.04, 30.80, 29.05, 29.02, 






Syntheses of Compounds 8a ((R)-3-(2-((R)-2-amino-3-
hydroxypropanamido)ethylthio)propane-1,2-diyl dipalmitate) and 8b ((S)-3-(2-
((R)-2-amino-3-hydroxypropanamido)ethylthio)propane-1,2-diyl dipalmitate). 
7a and 7b were deprotected with TFA as described
C15H31
for N-Boc deprotection (see syntheses of 6a, 6b). The title compounds were obtained 
as flaky white solids (99-100%). 
8a: 1H NMR (400 MHz, DMSO) δ 8.51 (t, J = 5.7, 1H), 8.08 (s, 1H), 5.47 (s, 1H), 
5.08 (dd, J = 4.5, 11.4, 1H), 4.31 (dd, J = 2.7, 11.9, 1H), 4.10 (dd, J = 7.1, 12.0, 1H), 
3.69 (dd, J = 9.1, 33.4, 3H), 3.28 (dd, J = 6.5, 13.3, 2H), 2.74 (ddd, J = 6.6, 14.1, 
21.4, 2H), 2.62 (t, J = 6.9, 2H), 2.32 – 2.19 (m, 4H), 1.56 – 1.45 (m, 4H), 1.23 (s, 













29.00, 28.92, 28.91, 28.74, 28.71, 28.70, 28.41, 28.36, 24.47, 24.39, 22.08, 13.92. MS 
(ESI) calculated for C40H78N2O6S, m/z 714.56, found 715.54 (M+H)
 +. 
8b: 1H NMR (400 MHz, DMSO) δ 8.51 (t, J = 5.4, 1H), 8.08 (s, 1H), 5.48 (s, 1H), 
5.09 (d, J = 5.8, 1H), 4.30 (dd, J = 2.6, 11.9, 1H), 4.10 (dd, J = 7.1, 11.9, 1H), 3.85 – 
3.57 (m, 3H), 3.32 – 3.26 (m, 2H), 2.80 (dd, J = 5.8, 14.1, 1H), 2.65 (ddd, J = 7.0, 
3.9, 20.3, 3H), 2.31 – 2.22 (m, 4H), 1.50 (d, J = 6.8, 4H), 1.23 (s, 48H), 0.84 (t, J = 
.7, 6H). 13C NMR (126 MHz, DMSO) δ 172.85, 172.63, 167.10, 70.25, 63.84, 60.65, 
4.71, 38.92, 33.92, 33.75, 31.66, 31.42, 31.17, 29.44, 29.41, 29.39, 29.30, 29.13, 
9.10, 29.09, 28.80, 28.75, 24.80, 22.46, 14.18. MS (ESI) calculated for C40H78N2O6S, 















Synthesis of Compound 9 ((R)-4-(iodomethyl)-2,2-dimethyl-1,3-dioxolane). 
To a solution of (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (compound 1a, 3.0 g, 
22.70 mmol) in toluene (50 mL) was added triphenylphosphine (PPh3; 37.15 g, 27.38 
mmol), imidazole (4.64 g, 68.10 mmol) and iodine (7.0 g, 29.51 mmol).213 The 
reaction mixture was stirred at 90 oC for 2 h. After removal of toluene under reduced 
9
 102
pressure, the residue was dissolved in DCM, washed with sat. Na2S2O3 (to quench the 
unreacted iodine), brine, and dried over Na2SO4. The solvent was then removed under 
yntheses of Compounds 10a ((R)-methyl 2-(tert-butoxycarbonylamino)-3-(((R)-
,2-dimethyl-1,3-dioxolan-4-yl)methylthio)propanoate) and 10b ((S)-methyl 2-
t-butoxycarbonylamino)-3-(((R)-2,2-dimethyl-1,3-dioxolan-4-
vacuum and the residue was purified by flash column chromatography 
(hexane:EtOAc = 49:1) to afford the literature compound 9214 as a colorless liquid 
(5.44 g, 99%).  
9: 1H NMR (400 MHz, CDCl3) δ 4.30 – 4.21 (m, 1H), 4.12 (dd, J = 6.1, 8.6, 1H), 
3.76 (dd, J = 5.4, 8.6, 1H), 3.23 (dd, J = 4.6, 9.8, 1H), 3.12 (dd, J = 8.5, 9.8, 1H), 1.43 
(s, 1H), 1.32 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 109.47, 74.63, 68.57, 26.11, 


















N-Boc protected L- and D- cysteine methyl esters were first obtained by treating H-L- 
and D-Cys-OMe●HCl (Sigma-Aldrich) with di-tert-butyl dicarbonate (Boc2O; 2.0 eq.) 
in DCM, followed by slow addition of triethylamine (TEA; 1.0 eq.) at 0 oC. DCM 
was removed under vacuum after the reaction was stirred at 0 oC for 2 h and the 
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residue was then purified by flash column chromatography with 10% EtOAc/hexane.) 
S-alkylation of Boc-L-Cys-OMe and Boc-D-Cys-OMe with 9 were then carried out. 
Compound 10 was synthesized as follows:  to a solution of 9 (900 mg, 3.72 mmol) in 
anhydrous DMF (8 mL) was added TEA (1.55 mL, 11.15 mmol), followed by Boc-L- 
or D-Cys-OMe (673 mg, 2.86 mmol). The reaction solution was stirred at 85 oC for 4 
 (400 MHz, CDCl3) δ 5.39 (d, J = 7.1, 1H), 4.52 (d, J = 7.3, 1H), 4.21 
, J = 6.2, 1H), 4.06 (dd, J = 6.1, 8.3, 1H), 3.74 (s, 3H), 3.66 (dd, J = 6.4, 8.3, 1H), 
.02 (d, J = 3.2, 2H), 2.73 (dd, J = 6.0, 13.4, 1H), 2.62 (dd, J = 6.5, 13.4, 1H), 1.43 (s, 
H), 1.40 (s, 3H), 1.33 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.49, 155.23, 
09.73, 80.18, 75.64, 68.68, 53.45, 52.58, 38.78, 35.22, 28.31, 26.84, 25.55. MS 
SI) calculated for C15H27NO6S, m/z 349.16, found 372.10 (M+Na)
 +.  
 
), 
.63 (dd, J = 6.3, 
 (s, 3H), 1.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
h.  After removal of DMF under vacuum, the residue was purified by flash column 
chromatography (hexane:EtOAc = 9:1) to afford 10a or 10b, respectively as viscous 
oils (60-63%).  






10b: 1H NMR (400 MHz, CDCl3) δ 5.43 (d, J = 7.0, 1H), 4.52 (s, 1H), 4.26 – 4.18
(m, 1H), 4.06 (dd, J = 6.1, 8.3, 1H), 3.76 (d, J = 11.0, 3H), 3.66 (dd, J = 6.5, 8.3, 1H
3.02 (ddd, J = 5.2, 13.8, 19.4, 2H), 2.75 (dd, J = 5.9, 13.5, 1H), 2
13.5, 1H), 1.43 (s, 9H), 1.41
171.49, 155.23, 109.73, 80.18, 75.64, 68.68, 53.45, 52.58, 35.78, 35.22, 28.31, 26.84, 









General procedure for acetonide deprotection and palmitoylation of the 1,2-
isopropylideneglycerol  unit: Synthesis of Compound 11 ((R)-3-((R)-2-amino-3-
methoxy-3-oxopropylthio)propane-1,2-diyl dipalmitate). 
To 10a (200 mg
O
, 0.57 mmol) was added 15 mL of 70% acetic acid (AcOH:H2O = 7:3) 
H), 
.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 173.66, 173.63, 
68.19, 69.95, 63.47, 53.73, 52.50, 34.24, 34.02, 32.91, 32.46, 31.94, 29.72, 29.70, 
and the reaction was stirred at r.t. for 24h. After complete removal of AcOH and 
water under reduced pressure, O-palmitoylation of the diol was carried out by 
sequential addition of pyridine (278 L, 3.44 mmol), a catalytic amount of DMAP, 
followed by palmitoyl chloride (709 L, 2.29 mmol) to the diol dissolved in 
anhydrous DCM (15 mL) and precooled to 0 oC. After stirring at 0 oC for 30 min, the 
reaction solution was brought to r.t. and stirred for 8 h.  After removal of solvent 
under vacuum, the residue was purified by flash column chromatography 
(hexane:EtOAc = 19:1) to afford the N-Boc-protected intermediate as a colorless oil. 
Finally, N-Boc deprotection was carried out as described earlier (see syntheses of 6a, 
6b) to obtain the title compound 11 as a white glassy solid (435 mg, 95%). 1H NMR 
(400 MHz, CDCl3) δ 8.01 (s, 2H), 5.13 (s, 1H), 4.41 – 4.06 (m, 3H), 3.81 (s, 3H), 














29.68, 29.52, 29.38, 29.30, 29.13, 24.85, 22.70, 14.13. MS (ESI) calculated for 














General Procedure for de-esterification of 10a and 10b, and subsequent coupling 
of serine: Syntheses of Compounds 12a-d. 
10a and 10b were de-esterified with aqueous LiOH (165 mg, 6.87 mmol dissolved in 
6mL water/15 mL THF) at r.t. for 10h. 1 M HCl solution was then added (to quench 
unreacted LiOH and to convert the lithium salt to the free-acid form) until a pH of 4 
was reached.  After removal of THF under vacuum, the residue was extracted thrice 
with DCM. The combined DCM layers were washed with brine and dried over 
Na2SO4. After removal of DCM under vacuum, H-L-Ser(tBu)-OtBu·HCl, or H-L-
Ser(tBu)-OMe·HCl, or H-D-Ser(tBu)-OMe·HCl (all from Bachem Americas, Inc., 
Torrance, CA, 437 mg, 2.06 mmol) were coupled to the de-esterified intermediates as 
described earlier for the syntheses of 7a and 7b. After removal of solvent under 
vacuum, the residue was purified by flash column chromatography (hexane:EtOAc = 






L-Cys-L-Ser 12a: X=t-Bu; 12b: X
L-Cys-D-Ser 12c: X=Me
D-Cys-L-Ser 12d : X=Me
 106
12a ((S)-tert-butyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate): 1H NMR (400 
Hz, CDCl3) δ 7.31 (s, 1H), 5.48 (s, 1H), 4.70 – 4.47 (m, 2H), 4.38 – 4.22 (m, 2H), 
.07 (dd, J = 6.1, 8.2, 1H), 3.79 – 3.71 (m, 1H), 3.67 (dd, J = 6.6, 8.2, 1H), 3.59 – 
.45 (m, 1H), 3.10 (d, J = 6.5, 1H), 2.96 (ddd, J = 6.1, 13.9, 43.9, 1H), 2.74 (ddd, J = 
.1, 13.5, 44.1, 1H), 1.43 (s, 18H), 1.33 (s, 3H), 1.22 (s, 3H), 1.11 (d, J = 4.0, 9H). 
S (ESI) calculated for C25H46N2O8S, m/z 534.30, found 557.29 (M+Na)
 +. 
2b ((S)-methyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
, 1H), 4.71 – 4.59 (m, 1H), 4.41 – 4.22 
 J = 7.3, 







dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate): 1H NMR (400 
MHz, CDCl3) δ 7.07 (d, J = 8.3, 1H), 5.48 (s
(m, 2H), 4.15 – 4.02 (m, 1H), 3.80 (dd, J = 2.9, 9.1, 1H), 3.72 (s, 3H), 3.68 (dd, J = 
6.5, 8.3, 1H), 3.55 (dd, J = 3.2, 9.1, 1H), 3.06 (ddd, J = 5.9, 12.2, 19.8, 1H), 2.98 – 
2.87 (m, 1H), 2.85 – 2.76 (m, 1H), 2.71 (dt, J = 6.8, 13.5, 1H), 1.44 (s, 9H), 1.42 (s, 
3H), 1.34 (s, 3H), 1.12 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.47, 170.41, 
155.28, 109.70, 75.70, 74.81, 73.52, 68.73, 61.69, 54.10, 53.12, 52.43, 35.61, 35.22, 
28.31, 27.30, 26.87, 25.56. MS (ESI) calculated for C22H40N2O8S, m/z 492.25, found 
515.18 (M+Na) +. 
12c ((R)-methyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate): 1H NMR (400 
MHz, CDCl3) δ 7.19 (s, 1H), 5.55 (s, 1H), 4.71 (d, J = 8.2, 1H), 4.39 (s, 1H), 4.35 – 
4.25 (m, 1H), 4.16 – 4.08 (m, 1H), 3.85 (d, J = 9.0, 1H), 3.76 (s, 3H), 3.70 (t,
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2.71 (m, 2H), 1.48 (s, 9H), 1.45 (s, 3H), 1.38 (s, 3H), 1.15 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 170.60, 170.34, 155.39, 109.70, 75.52, 74.79, 73.50, 68.68, 61.75, 
53.99, 52.86, 52.41, 35.51, 30.95, 28.31, 27.30, 26.88, 25.52. MS (ESI) calculated for 
C22H40N2O8S  m/z 492.25, found 515.18 (M+Na)
 +. 
12d ((S)-methyl 3-tert-butoxy-2-((S)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate):  1H NMR (400 
MHz, CDCl3) δ 7.07 (d, J = 8.3, 1H), 5.48 (s, 1H), 4.71 – 4.59 (m, 1H), 4.41 – 4.22 
(m, 2H), 4.15 – 4.02 (m, 1H), 3.80 (dd, J = 2.9, 9.1, 1H), 3.72 (s, 3H), 3.68 (dd, J = 
6.5, 8.3, 1H), 3.55 (dd, J = 3.2, 9.1, 1H), 3.06 (ddd, J = 5.9, 12.2, 19.8, 1H), 2.98 – 
2.87 (m, 1H), 2.85 – 2.76 (m, 1H), 2.71 (dt, J = 6.8, 13.5, 1H), 1.44 (s, 9H), 1.42 (s, 
3H), 1.34 (s, 3H), 1.12 (s, 9H). MS (ESI) calculated for C22H40N2O8S, m/z 492.25, 




























Syntheses of Compounds 13a-d. 
Acetonide deprotection followed by O-palmitoylation of 12a-d were performed as per 
the general procedure outlined earlier (synthesis of compound 11) to afford the 
corresponding compounds 13a-d in 90-95% yields. 
13a ((R)-3-((R)-2-(tert-butoxycarbonylamino)-3-((S)-1,3-di-tert-butoxy-1- 
oxopropan-2-ylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate): 1H NMR 
(400 MHz, CDCl3) δ 7.02 (d, J = 7.9, 1H), 5.37 (s, 1H), 5.19 – 5.09 (m, 1H), 4.51 (dt, 
J = 2.9, 8.0, 1H), 4.31 (dd, J = 3.5, 11.9, 2H), 4.14 (dd, J = 5.9, 11.9, 1H), 3.76 (dd, J 
= 2.9, 8.8, 1H), 3.51 (dd, J = 3.0, 8.8, 1H), 2.93 (d, J = 6.2, 2H), 2.79 (d, J = 6.1, 2H), 
2.30 (ddd, J = 5.8, 10.8, 12.0, 4H), 1.59 (dd, J = 6.6, 12.8, 5H), 1.43 (d, J = 2.6, 17H), 
1.23 (s, 48H), 1.12 (d, J = 2.6, 9H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.40, 173.13, 170.13, 168.92, 81.97, 73.17, 70.32, 63.52, 61.97, 53.51, 
5.61, 34.31, 34.11, 33.71, 33.13, 31.94, 29.72, 29.68, 29.66, 29.53, 29.38, 29.33, 
9.32, 29.16, 29.15, 28.30, 28.02, 27.34, 24.90, 24.74, 22.71, 14.14. MS (ESI) 
alculated for C54H102N2O10S, m/z 970.73, found 993.82 (M+Na)
 +.   
3b ((R)-3-((R)-3-((S)-3-tert-butoxy-1-methoxy-1-oxopropan-2-ylamino)-2-(tert-
utoxycarbonylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate): 1H NMR 
00 MHz, CDCl3) δ 7.06 (d, J = 8.1, 1H), 5.17 (s, 1H), 4.69 – 4.58 (m, 1H), 4.31 
d, J = 3.5, 11.9, 2H), 4.15 (dd, J = 5.9, 11.9, 1H), 3.80 (dd, J = 3.0, 9.1, 1H), 3.72 
, 3H), 3.55 (dd, J = 3.2, 9.1, 1H), 2.94 (d, J = 6.1, 2H), 2.79 (d, J = 5.9, 2H), 2.29 
d, J = 4.9, 7.5, 4H), 1.59 (s, 4H), 1.43 (s, 9H), 1.23 (s, 48H), 1.12 (s, 9H), 0.86 (t, J 












73.51, 70.29, 63.49, 61.67, 53.14, 52.41, 35.52, 34.30, 34.09, 33.20, 31.93, 29.71, 
-oxopropan-2-ylamino)-2-(tert-
itate): 1H NMR 
29.51, 29.37, 29.32, 29.31, 29.15, 29.14, 28.29, 27.29, 24.90, 24.88, 22.70, 14.13. MS 
(ESI) calculated for C51H96N2O10S, m/z 928.68, found 951.57 (M+Na)
 +. 
13c ((R)-3-((R)-3-((R)-3-tert-butoxy-1-methoxy-1
butoxycarbonylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate): 1H NMR 
(400 MHz, CDCl3) δ 7.15 – 7.06 (m, 1H), 5.19 – 5.11 (m, 1H), 4.65 (d, J = 8.4, 1H), 
4.31 (dd, J = 3.6, 11.9, 2H), 4.14 (dd, J = 5.9, 11.9, 1H), 3.81 (dd, J = 2.9, 9.0, 1H), 
3.72 (s, 3H), 3.53 (dd, J = 3.3, 9.0, 1H), 2.94 (dd, J = 14.0, 20.2, 2H), 2.78 (s, 2H), 
2.29 (dd, J = 7.5, 13.4, 4H), 1.59 (d, J = 6.7, 4H), 1.44 (s, 9H), 1.23 (s, 47H), 1.12 (d, 
J = 1.9, 9H), 0.86 (t, J = 6.9, 6H). 13C NMR (126 MHz, CDCl3) δ 173.76, 172.63, 
171.22, 170.29, 73.10, 70.42, 63.59, 55.56, 52.96, 34.36, 34.05, 31.93, 30.96, 29.73, 
29.68, 29.61, 29.55, 29.38, 29.32, 29.15, 19.12, 24.84, 22.70, 14.13. MS (ESI) 




(400 MHz, CDCl3) δ 7.06 (d, J = 8.1, 1H), 5.17 (s, 1H), 4.69 – 4.58 (m, 1H), 4.31 
(dd, J = 3.5, 11.9, 2H), 4.15 (dd, J = 5.9, 11.9, 1H), 3.80 (dd, J = 3.0, 9.1, 1H), 3.72 
(s, 3H), 3.55 (dd, J = 3.2, 9.1, 1H), 2.94 (d, J = 6.1, 2H), 2.79 (d, J = 5.9, 2H), 2.29 
(td, J = 4.9, 7.5, 4H), 1.59 (s, 4H), 1.43 (s, 9H), 1.23 (s, 48H), 1.12 (s, 9H), 0.86 (t, J 










General Procedure for one-step deprotection of N-Boc and O-tBu: Syntheses of 
Compounds 14a-d. 
13a-d were deprotected with dry TFA as described earlier (general procedure for N-
Boc deprotection) which allowed for the simultaneous deprotection of the N-Boc and 
O-tBu groups. Consequently, 14a was obtained as the –Ser-OH (free acid), while 
14b-d were the –Ser-OMe esters. All title compounds (14a-d) were obtained as white 
glassy solids in near-quantitative yields. 
14a ((S)-2-((R)-2-amino-3-((R)-2,3-bis(palmitoyloxy)propylthio)propanamido)-3-
hydroxypropanoic acid): 1H NMR (400 MHz, DMSO) δ 9.10 (d, J = 7.4, 1H), 8.82 
(d, J = 7.9, 1H), 8.23 (s, 1H), 5.16 (d, J = 7.5, 1H), 4.81 – 4.58 (m, 1H), 4.42 – 4.23 
(m, 2H), 4.18 – 4.07 (m, 1H), 3.79 (dd, J = 4.8, 11.0, 1H), 3.70 – 3.58 (m, 1H), 3.07 
(dt, J = 6.7, 13.0, 1H), 2.94 – 2.65 (m, 3H), 2.31 – 2.13 (m, 4H), 1.55 – 1.44 (m, 4H), 
1.22 (s, 48H), 0.84 (t, J = 6.7, 6H). 13C NMR (126 MHz, DMSO) δ 179.71, 177.74, 
177.51, 176.39, 74.88, 68.75, 66.29, 60.04, 56.60, 38.87, 38.78, 38.61, 38.23, 36.53, 


















29.62, 27.32, 19.16. MS (ESI) calculated for C41H78N2O8S, m/z 758.55, found 759.66 
+H) +. 
4b ((R)-3-((R)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-
xopropylthio)propane-1,2-diyl dipalmitate): 1H NMR (500 MHz, CDCl3) δ 8.21 
, 1H), 5.28 (s, 1H), 5.20 – 5.07 (m, 1H), 4.79 – 4.60 (m, 2H), 4.47 – 4.26 (m, 2H), 
.14 – 4.04 (m, 1H), 3.99 – 3.90 (m, 1H), 3.74 (s, 3H), 3.24 – 2.97 (m, 2H), 2.75 (s, 
 
27, 70.08, 63.65, 63.52, 61.90, 52.92, 
itate): 1H NMR (400 MHz, CDCl3) δ 8.86 – 






2H), 2.36 – 2.23 (m, 4H), 1.57 (s, 4H), 1.23 (s, 48H), 0.86 (t, J = 7.0, 6H). 13C NMR
(126 MHz, CDCl3) δ 174.39, 173.97, 169.90, 70.
34.32, 34.05, 31.93, 29.73, 29.68, 29.55, 59.53, 29.38, 29.0, 29.14, 29.11, 24.89, 




8.37 (m, 1H), 5.40 – 5.22 (m, 1H), 5.21 – 5.01 (m, 1H), 4.72 – 4.42 (m, 2H), 4.42 – 
4.16 (m, 2H), 4.08 (s, 1H), 4.01 – 3.88 (m, 1H), 3.73 (s, 3H), 3.39 – 2.98 (m, 2H), 
2.73 (s, 2H), 2.29 (s, 4H), 1.56 (s, 4H), 1.23 (s, 48H), 0.85 (t, J = 6.8, 6H). 13C NMR 
(126 MHz, CDCl3) δ 174.22, 173.92, 70.02, 69.83, 63.66, 63.60, 53.02, 34.30, 34.05, 
31.94, 29.73, 29.69, 29.56, 29.55, 29.39, 29.32, 29.16, 29.13, 24.88, 24.83, 22.70, 
14.13. MS (ESI) calculated for C42H80N2O8S, m/z 772.56, found 773.53 (M+H)
+. 
14d ((R)-3-((S)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-
oxopropylthio)propane-1,2-diyl dipalmitate): 1H NMR (400 MHz, CDCl3) δ 8.74 
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3.99 (s, 2H), 3.78 (s, 3H), 3.23 (s, 2H), 2.78 (s, 2H), 2.33 (s, 4H), 1.61 (s, 4H), 1.61 
(s, 3H), 1.27 (s, 48H), 0.89 (t, J = 6.7, 6H). 13C NMR (126 MHz, CDCl3) δ 174.49, 
lan-
173.76, 70.42, 63.59, 55.56, 53.70, 52.96, 48.56, 34.36, 34.05, 31.93, 29.73, 29.68, 
29.55, 29.38, 29.32, 29.15, 29.12, 24.84, 22.70, 14.13. MS (ESI) calculated for 
C42H80N2O8S, m/z 772.56, found 773.53 (M+H)
+. 
 












Synthesis of compound 15 (ethyl 3-(((S)-2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy)-2-hydroxypropanoate). 
To a solution of ethyl-2,3-epoxypropanoate (Sigma-Aldrich, Inc., 375 mg, 2.91 mmol) 
in anhydrous DCM (10 mL) was added boron trifluoride diethyl etherate (BF3●OEt2; 
83 mg, 0.58 mmol), followed by (S)-(+)- 2,2-dimethyl-1,3-dioxolane-4-methanol (1a, 
1.20 g, 8.72 mmol).215  The reaction mixture was stirred at r.t. for 5 h.  After removal 
of solvent under reduced pressure, a mixture of ethyl 3-((2,2-dimethyl-1,3-dioxo
4-yl)methoxy)-2-hydroxypropanoate (compound 15) and (S)-(+)- 2,2-dimethyl-1,3-
dioxolane-4-methanol (unreacted starting material, 1a) were obtained. The Rf values 
of both the required product as well as the starting material were identical which 
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presented difficulty in chromatographic isolation. The mixture was therefore 
subjected to selective protection of the primary hydroxyl group of the acetonide-
protected glycerol 1a with TBDMSCl (tert-butyldimethylsilyl chloride), which 
allowed the facile isolation of compound 15 by flash column chromatography using 
20% EtOAc/hexane (433 mg, 60%). 1H NMR (400 MHz, CDCl3) δ 4.34 – 4.22 (m, 
H), 4.05 (dd, J = 6.4, 8.3, 1H), 3.88 – 3.80 (m, 2H), 3.75 (ddd, J = 6.3, 7.5, 8.2, 1H), 
, 3.15 (dd, J = 6.6, 15.6, 1H), 1.44 – 1.27 (m, 9H). 13C NMR (126 
Hz, CDCl3) δ 171.49, 171.44, 108.42, 73.59, 73.55, 72.11, 72.04, 71.56, 69.95, 
9.85, 65.57, 65.54, 60.85, 28.68, 25.68, 25.67, 24.37, 24.33, 13.17. MS (ESI) 
alculated for C11H10O6, m/z 248.13, found 271.12 (M+Na
+) and 519.245  
+M+Na) +. 
4












Synthesis of compound 16 (ethyl 3-(((S)-2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy)-2-tosyloxy)propanoate). 
O-tosylation was performed by sequentially adding TEA (590 µL, 4.23 mmol) and p-
TsCl (806 mg, 4.23 mmol) to a solution of 15 (350 mg, 1.41 mmol) in anhydrous 
DCM (10 mL) cooled to 0 oC. The reaction mixture was brought to r.t. and stirred for 
8 h. After removal of solvent under vacuum, the residue was purified by flash column 




78%). 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.4, 2H), 7.31 (d, J = 8.0, 2H), 5.02 
– 4.96 (m, 1H), 4.18 – 4.06 (m, 3H), 3.96 – 3.77 (m, 3H), 3.62 (ddd, J = 3.4, 6.3, 8.4, 
1H), 3.54-3.38 (m, 2H), 2.42 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H), 1.19 (t, J = 7.1, 3H). 
13C NMR (126 MHz, CDCl3) δ 165.34, 143.94, 132.12, 132.09, 128.55, 126.92, 
108.23, 108.20, 75.73, 73.22, 71.20, 69.59, 65.31, 60.90, 25.48, 24.18, 20.49, 12.77. 












mpound 17 (ethyl 2-azido-3-(((S)-2,2-dimethyl-1,3-dioxolan-4-
l)methoxy)propanoate). 
o a solution of compound 16 (380 mg, 0.94 mmol) in anhydrous DMF (10 mL) was 
dded sodium azide (184 mg, 2.83 mmol).  The reaction mixture was stirred at r.t. for 
2 h.  After removal of DMF under vacuum, the reaction residue was dissolved in 
l of solvent 





DCM, washed with water, brine, and dried over Na2SO4. After remova
under reduced pressure, the residue wa
(hexane:EtOAc = 9:1) to afford the title compound 17 (245 mg, 95%). 1H NMR (400 
MHz, CDCl3) δ 4.29 – 4.18 (m, 3H), 3.74 (ddd, J = 6.2, 8.4, 11.2, 1H), 3.61 – 3.48 
(m, 2H), 1.39 (d, J = 0.9, 3H), 1.32 (d, J = 5.0, 3H), 1.29 (t, J = 7.1, 3H). 13C NMR 
(126 MHz, CDCl3) δ 166.54, 107.70, 107.67, 72.67, 70.55, 69.89, 64.82, 60.53, 59.86, 
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Synthesis of compound 18 (ethyl 2-(tert-butoxycarbonylamino)-3-(((S)2,2-
imethyl-1,3-dioxolan-4-yl)methoxy)propanoate).  
eduction of the azide to the amine under Staudinger conditions.216 To 17 (230 mg, 
.84 mmol) dissolved in THF (8 mL) and H2O (30.3 mg, 1.68 mmol) was added PPh3 
l of 
e was dissolved in anhydrous DCM (5 mL) and di-tert-




(265 mg, 1.01 mmol). The reaction mixture was refluxed for 6 h. After remova
solvent, the reaction residu
butyl dicarbonate (Boc2O; 551 mg, 2.52 mmol) and TEA (351 µL, 2.52 mmol) was 
added and stirred at r.t. for 8h. The solvent was removed under vacuum and the 
residue was purified by flash column chromatography (hexane:EtOAc = 17:3) to 
afford the title compound 18 (272 mg, 93%). 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J 
= 8.2, 1H), 4.42 – 4.32 (m, 1H), 4.26 – 4.13 (m, 3H), 3.99 (dd, J = 6.4, 8.3, 1H), 3.94 
– 3.86 (m, 1H), 3.75 – 3.63 (m, 2H), 3.55 – 3.40 (m, 2H), 1.43 (s, 9H), 1.38 (d, J = 
1.9, 3H), 1.33 (d, J = 0.6, 3H), 1.25 (t, J = 7.1, 3H). 13C NMR (126 MHz, CDCl3) δ 
168.21, 153.15, 107.09, 77.59, 70.07, 69.60, 69.36, 64.18, 59.17, 51.70, 25.95, 24.32, 






















), 3.84 – 3.76 (m, 1H), 3.75 – 3.67 (m, 4H), 3.64 – 3.50 (m, 4H), 1.44 (s, 
b
yl)methoxy)propanamido)propanoate) and 19b ((R)-methyl 3-tert-butoxy-2
(tert-butoxycarbonylamino)-3-(((S)-2,2-dimethyl-1,3
yl)methoxy)propanamido)propanoate). 
De-esterification of the ethyl ester of 18 and subsequent coupling to H-L- and -D-
Ser(tBu)-OMe●HCl were performed as described for the syntheses of compounds 
12a-d to yield 19a and 19b, respectively (70-75%). 
19a: 1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 5.48 (s, 1H), 4.71 – 4.62 (m, 1H), 
4.25 (dt, J = 5.9, 11.7, 2H), 4.06 – 3.98 (m, 1H), 3.89 (ddd, J = 2.4, 4.0, 9.5, 1H), 3.82 
– 3.68 (m, 5H), 3.66 – 3.50 (m, 4H), 1.44 (s, 9H), 1.40 (d, J = 2.4, 3H), 1.33 (d, J = 
2.2, 3H), 1.15-1.08 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 168.88, 168.87, 168.81, 
108.18, 73.14, 62.15, 71.24, 71.00, 69.90, 65.30, 65.06, 60.56, 51.78, 51.03, 28.38, 
26.98, 25.97, 25.43, 24.10. MS (ESI) calculated for C22H40N2O9, m/z 476.27, found 
499.19 (M+Na) +. 
19b: 1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 5.49 (s, 1H), 4.66 (ddd, J = 3.2, 7.2, 
11.3, 1H), 4.25 (ddd, J = 5.7, 11.6, 17.0, 2H), 4.06 – 3.98 (m, 1H), 3.89 (ddd, J = 2.4, 
4.0, 9.5, 1H
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9H), 1.42 – 1.38 (m, 3H), 1.36 – 1.31 (m, 3H), 1.13-1.08 (m, 9H). 13C NMR (126 
Hz, CDCl3) δ 167.90, 167.83, 107.19, 72.16, 71.16, 70.27, 70.03, 68.94, 64.32, 
4.09, 59.58, 50.80, 50.05, 27.40, 26.00, 24.99, 24.46, 23.12. MS (ESI) calculated for 
22H40N2O9, m/z 476.27, found 499.19 (M+Na)
 +. 
no)-3-oxopropoxy)propane-











Syntheses of compounds 20a ((S)-3-(3-((S)-3-tert-butoxy-1-methoxy-1-
oxopropan-2-ylamino)-2-(tert-butoxycarbonylami
1,2-diyl dipalmitate), and 20b ((S)-3-(3-((R)-3-tert-butoxy-1-methoxy-1-
oxopropan-2-ylamino)-2-(tert-butoxycarbonylamino)-3-oxopropoxy)propane-
1,2-diyl dipalmitate). 
Acetonide deprotection and O-palmitoylation were performed as described earlier 
(see syntheses of 13a-d). 20a or 20b were obtained in 80-83% yield. 
20a: 1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 8.3, 1H), 5.40 (s, 1H), 5.16 (dd, J = 
3.3, 5.5, 1H), 4.66
3.96 – 3.76 (m, 2H), 3.71 (d, J = 1.5, 3H), 3.66 – 3.49 (m, 4H), 2.28 (dd, J = 7.7, 
15.5, 4H), 1.58 (d, J = 5.7, 4H), 1.44 (s, 9H), 1.23 (s, 48H), 1.13 – 1.08 (m, 9H), 0.85 


















154.25, 79.11, 72.29, 69.96, 69.69, 68.70, 68.63, 68.58, 68.55, 68.48, 68.44, 68.41, 
61.19, 60.94, 51.90, 51.66, 51.17, 33.06, 32.91, 30.74, 28.52, 28.48, 28.32, 28.18, 
18.12, 27.94, 27.11, 26.09, 23.70, 21.51, 12.94. MS (ESI) calculated for C51H96N2O11, 
m/z 912.70, found 935.54 (M+Na) +. 
20b: 1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 9.0, 1H), 5.40 (s, 1H), 5.23 – 5.11 (m, 
H), 4.66 (tt, J = 3.0, 8.6, 1H), 4.30 (ddd, J = 4.3, 10.2, 15.3, 2H), 4.11 (ddt, J = 5.0, 
.0, 10.3, 1H), 3.91 – 3.76 (m, 2H), 3.71 (d, J = 1.3, 3H), 3.68 – 3.49 (m, 4H), 2.28 
d, J = 7.8, 15.5, 4H), 1.58 (dd, J = 6.9, 12.8, 4H), 1.44 (s, 9H), 1.23 (s, 48H), 1.14 – 
.07 (m, 9H), 0.85 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 171.84, 171.56, 








68.08, 60.86, 60.31, 51.57, 51.32, 50.84, 32.74, 32.58, 30.41, 28.19, 28
27.85, 27.79, 27.62, 26.78, 25.72, 23.38, 21.18, 12.61. MS (ESI) calculated 


























Syntheses of compound 21a ((S)-3-(2-amino-3-((S)-3-hydroxy-1-methoxy-1-
oxopropan-2-ylamino)-3-oxopropoxy)propane-1,2-diyl dipalmitate; 
trifluoroacetate) and 21b ((S)-3-(2-amino-3-((R)-3-hydroxy-1-methoxy-1-
oxopropan-2-ylamino)-3-oxopropoxy)propane-1,2-diyl dipalmitate; 
68.50, 68.31, 68.22, 67.59, 61.22, 
1.10, 60.49, 54.08, 53.97, 51.92, 51.63, 51.47. 32.90, 32.78, 30.63, 28.42, 28.37, 
8.24, 28.08, 28.02, 27.85, 27.80, 23.55, 21.40, 12.82. MS (ESI) calculated for 
42H80N2O9, m/z 756.59, found 757.45 (M+H)
 +. 
1b: 1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 8.04 (s, 1H), 5.28 (s, 1H), 5.15 (s, 
H), 4.58 (d, J = 51.7, 2H), 4.18 (d, J = 42.7, 2H), 3.90 (s, 3H), 3.76 (d, J = 14.5, 
H), 3.59 (s, 2H), 2.28 (dd, J = 7.4, 11.7, 4H), 1.56 (s, 4H), 1.23 (s, 48H), 0.86 (t, J = 
.8, 6H). 13C NMR (126 MHz, CDCl3) δ 172.11, 171.82, 171.76, 171.69, 168.06, 
7.84, 67.64, 67.55, 66.89, 60.55, 60.41, 59.84, 53.42, 53.32, 51.27, 50.98, 50.82, 
trifluoroacetate). 
One-step deprotection of the N-Boc and O-tBu groups utilizing TFA was carried out 
as described earlier (syntheses of 14a-d). Title compounds were obtained as white 
glassy solids 21a or 21b (99-100%). 
21a: 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.03 (d, J = 28.1, 1H), 5.28 (s, 1H), 
5.15 (s, 1H), 4.71 (dd, J = 69.3, 103.2, 2H), 4.17 (ddd, J = 7.3, 17.4, 18.6, 2H), 4.06 – 
3.81 (m, 3H), 3.76 (d, J = 14.3, 3H), 3.58 (dd, J = 10.2, 15.7, 2H), 2.28 (dd, J = 7.3, 
11.9, 4H), 1.56 (s, 4H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, 










32.24, 32.14, 29.97, 27.76, 27.72, 27.58, 27.42, 27.35, 27.19, 27.14, 22.89, 2
12.16. MS (ESI) calculated for C42H80N2O9, m/z 756.59, found 757.45 (M
 




 to the reaction vessel at 0 oC.  After 







Synthesis of compound 22 ((S)-4-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane). 
O-benzylation of 1a was performed by first adding sodium hydride (NaH; 60% in 
mineral oil, 363 mg) to a solution of (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol 
(1a, 200 mg, 1.51 mmol) in anhydrous DMF (5 mL) on ice. After stirring for 10 min, 
benzyl bromide (BnBr; 360 L, 3.03 mmol) was added slowly to the reaction 
mixture.  The reaction was brought to r.t. after 30 min and stirred for an additional 8 
h. NaH was quenched by slowly adding methanol
22
removal of solvent, the residue was dissolved in DCM and washed with water (1X) 
and the resulting water layer was extracted with DCM (3X). The combined DCM 
layers were washed with brine and dried over Na2SO4.  After removal of solvent, the 
residue was purified by flash column chromatography (hexane:EtOAc = 19:1) to 
yield the title compound 22 (330 mg, 98%). 1H NMR (400 MHz, CDCl3) δ 7.36 – 
 121
J = 6.4, 8.3, 1H), 3.73 (dd, J = 6.3, 8.3, 1H), 3.54 (dd, J = 5.7, 9.8, 1H), 3.46 (dd, J = 
5.5, 9.8, 1H), 1.40 (s, 3H), 1.35 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 136.87, 
27.39, 126.73, 126.71, 108.39, 73.68, 72.47, 70.00, 65.81, 25.74, 24.35. MS (ESI) 














Synthesis of compound 23 ((R)-((2,3-bis(hexadecyloxy)propoxy)methyl)benzene). 
Deprotection of the acetonide protecting group of 22 was achieved by stirring the 
compound (180 mg, 0.81 mmol) in 70% acetic acid (AcOH:H2O = 7:3) as described 
for the syntheses of 4a and 4b. After complete removal of acetic acid and water under 
reduced pressure, the residue was dissolved in DMF (5 mL) and cooled to 0 oC.  The 
resulting diol was O-alkylated with 1-iodohexacecane (1.14g, 3.24 mmol) in the 
presence of NaH (60 % in mineral oil, 770 mg) in anhydrous DMF (8 mL) at 0 oC.  
The reaction mixture was stirred for 30 min at 0 oC and the temperature was then 
raised to r.t. for 8 h. The excess NaH was quenched by slowly adding methanol to the 
reaction at 0 oC.  After removal of solvent, the residue was dissolved in DCM and 
washed with water (1X). And the resulting water layer was extracted with DCM (3X). 
The combined DCM layers were washed with brine and dried over Na2SO4.  After 
removal of solvent under vacuum, the residue was purified by flash column 
 122
chromatography (hexane:EtOAc = 49:1) to afford a white solid (470 mg, 92%). 1H 
NMR (400 MHz, CDCl3) δ 7.31 (d, J = 4.3, 4H), 7.28 – 7.24 (m, 1H), 4.54 (s, 2H), 
3.62 – 3.44 (m, 7H), 3.41 (t, J = 6.7, 2H), 1.60 – 1.47 (m, 4H), 1.26 (d , 52H), 0.86 (t, 
J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 138.42, 128.31, 127.58, 77.88, 73.34, 
1.66, 70.79, 70.62, 70.24, 31.93, 30.09, 29.72, 29.66, 29.52, 29.38, 26.10, 22.70, 










Synthesis of compound 24 ((R)-2,3-bis(hexadecyloxy)propyl 4-
methylbenzenesulfonate). 
O-debenzylation followed by O-tosylation of 23 en route to the iodo intermediate 25 
was obtained as follows: Hydrogenolysis of 23 (500 mg, 0.79 mmol) dissolved in a 
mixture of 20 mL MeOH/DCM (1:1) was carried out using  Pd(OH)2/C (500 mg) and 
H2 at 55 psi in a Parr apparatus for 8 h. The catalyst was removed by filtration over 
celite, and the solvent was removed to afford the O-debenzylated intermediate as a 
white solid (425 mg, ~100%). After drying completely, the solid was dissolved in 
anhydrous CH3CN (15 mL), followed by addition of pyridine (320 L, 3.96 mmol) 
and a catalytic amount of DMAP.  Then p-TsCl (755 mg, 3.96 mmol) was added and 






vacuum, the residue was purified by flash column chromatography (hexane:EtOAc = 
17:1) to afford the title compound 24 (527 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 
7.77 (d, J = 8.2, 2H), 7.31 (d, J = 8.5, 2H), 4.13 (dd, J = 4.1, 10.3, 1H), 4.00 (dd, J = 
5.8, 10.3, 1H), 3.62 – 3.54 (m, 1H), 3.47 – 3.41 (m, 2H), 3.38 (t, 2H), 3.33 (t, J = 6.7, 
2H), 2.42 (s, 3H), 1.45 (s, 4H), 1.23 (s, 52H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 
MHz, CDCl3) δ 143.66, 131.93, 128.75, 126.98, 75.16, 70.75, 69.80, 68.64, 68.30, 
0.91, 28.85, 28.69, 28.65, 28.63, 28.60, 28.50, 28.46, 28.44, 28.35, 25.01, 24.94, 












Synthesis of compound 25 ((R)-1-(1-(hexadecyloxy)-3-iodopropan-2-
yloxy)hexadecane). 
The O-tosyl derivative 24 was converted to the iodo derivative 25. Iodine (310 mg, 
12.23 mmol) and potassium iodide (KI; 2.03 g, 12.23 mmol) were added to a solution 
of 25 (850 mg, 1.22 mmol) in anhydrous DMF (15 mL) and the reaction was stirred at 
80 oC for 24 h. After removal of DMF under vacuum, the residue was diluted with 






was removed and the residue was purified by flash column chromatography 
(hexane:EtOAc = 49:1) to yield the title compound 25 (700 mg, 88%). 1H NMR (400 
MHz, CDCl3) δ 3.51 (m, 3H), 3.45 – 3.39 (m, 3H), 3.37 – 3.24 (m, 3H), 1.60 – 1.50 
(m, 4H), 1.23 (s, 52H), 0.86 (t, J = 6.9, 6H). 13C NMR (126 MHz, CDCl3) δ 76.40, 
70.86, 70.73, 69.25, 30.91, 28.91, 28.69, 28.66, 28.65, 28.61, 28.45, 28.43, 28.35, 
25.09, 25.07, 21.68, 13.11, 6.39. MS (ESI) calculated for C35H71IO2, m/z 650.45, 















Synthesis of compound 26 ((6R,10R)-methyl 10-(hexadecyloxy)-2,2-dimethyl-4-
xo-3,12-dioxa-8-thia-5-azaoctacosane-6-carboxylate). 
-L-Cys-OMe 
 and TEA (445 L, 3.20 mmol) were added to the solution of 25 
o
S-alkylation of Boc-L-Cys-OMe with 25 was carried out as follows: Boc
(752 mg, 3.20 mmol)
(260 mg, 0.40 mmol) in anhydrous DMF (8 mL). The reaction was stirred at 85 oC for 
2h. After removal of DMF under vacuum, the residue was purified by flash column 
chromatography (hexane:EtOAc = 19:1) to afford the title compound 26 (291 mg, 
96%). 1H NMR (500 MHz, CDCl3) δ 5.53 (d, J = 8.0, 1H), 4.51 (s, 1H), 3.73 (s, 3H), 
3.48 (m, 5H), 3.40 (m, 6.7, 2H), 3.07 – 2.93 (m, 2H), 2.75 (dd, J = 4.9, 13.7, 1H), 
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2.63 (dd, J = 6.0, 13.7, 1H), 1.57 – 1.49 (m, 4H), 1.42 (s, 9H), 1.31 – 1.20 (m, 52H), 
0.85 (t, J = 7.0, 6H). 13C NMR (126 MHz, CDCl3) δ 170.63, 154.23, 28.97, 77.55, 
70.68, 70.28, 69.55, 52.47, 51.47, 34.44, 33.51, 30.90, 28.97, 28.69, 28.64, 28.35, 
27.28, 25.08, 25.05, 21.68, 13.13. MS (ESI) calculated for C44H87O6S, m/z 757.63, 

















Synthesis of compound 27 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-
2-(hexadecyloxy)-2,2-dimethyl-7-oxo-3,14-dioxa-10-thia-6-azatriacontane-5-
) via procedures similar to 
1
carboxylate). 
Compound 26 was obtained as a viscous oil (228 mg, 64%
those described for the syntheses of compounds 12a-d. 1H NMR (500 MHz, CDCl3) δ 
5.60 (s, 1H), 4.64 (d, J = 8.1, 1H), 4.30 (s, 1H), 3.79 (dd, J = 3.0, 9.1, 1H), 3.71 (s, 
3H), 3.60 – 3.47 (m, 7H), 3.45 – 3.35 (m, 2H), 2.95 (dd, J = 5.8, 13.9, 1H), 2.87 (dd, 
J = 6.9, 13.8, 1H), 2.78 (s, 2H), 1.58 – 1.49 (m, 4H), 1.43 (s, 6H), 1.30 – 1.20 (m, 
52H), 1.11 (s, 8H), 0.85 (t, J = 7.0, 6H). 13C NMR (126 MHz, CDCl3) δ 169.58. 
169.46, 154.24, 77.23, 72.40, 70.68, 70.27, 69.54, 60.72, 52.13, 51.33, 34.57 33.34, 
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30.90, 28.95, 28.69, 28.64, 28.62, 28.50, 28.35, 27.28, 26.26, 25.08, 25.03, 21.68, 

















N-Boc deprotection with neat TFA was performed as described for the synthesis of 
and 6b. 
1H NMR (400 M
1H), 3.74 (s, 3H), 3.61 – 3.48 (m, 3H), 3.47 – 3.37 (m, 3H), 3.18 – 3.07 (m, 1H), 3.01 
– 2.89 (m, 1H), 2.86 – 2.66 (m, 1H), 1.59 – 1.47 (m, 4H), 1.23 (s, 48H), 0.86 (t, J = 
6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 170.05, 77.85, 71.80, 71.12, 70.91, 61.75, 
55.32, 53.06, 52.74, 34.98, 34.32, 31.93, 29.73, 29.68, 29.55, 29.51, 29.42, 29.38, 

























Synthesis of compound 30 ((R)-methyl 3-hydroxy-2-palmitamidopropanoate). 
-palmitoylation of 29 was carried out as follows: H-D-Ser-OMe●HCl (29) was N-
 of sat. aqueous 
n EtOAc (10 
ing palmitoyl chloride (377 L, 1.24 mmol) dropwise to the 
bined EtOAc layers were washed with brine and dried over Na2SO4. After 
.37, 29.36, 29.26, 25.59, 22.69, 14.12. MS (ESI) calculated for 
20H39NO4, m/z 357.29, found 358.30 (M+H)
+ and 380.28 (M+Na)+. 
N
acylated by first generating the free-base by the addition of 10 mL
NaHCO3 solution to a solution of 29 (200 mg, 1.04 mmol, Bachem) i
mL), and then add
reaction. The reaction mixture, after stirring for 1 h, was extracted with EtOAc (3X). 
The com
removal of solvent under vacuum, the residue was purified by flash column 
chromatography (hexane:EtOAc = 7:3) to afford the title compound as a white solid 
(286 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 6.61 (s, 1H), 4.65 – 4.58 (m, 1H), 3.92 
(dd, J = 3.6, 11.1, 1H), 3.83 (d, J = 11.1, 1H), 3.73 (s, 3H), 2.25 – 2.18 (m, 3H), 1.64 
– 1.54 (m, 2H), 1.27 – 1.18 (m, 24H), 0.83 (t, J = 6.9, 3H). 13C NMR (126 MHz, 


















Compound 30 was acetonide protected with 2,2-dimethyoxypropane (2,2-DMP; 
mL, 195.8 mmol) and pyridinium p-toluenesulfonate (PPTS; 281 mg, 1.12 mmol) by 
adding the above reagents to compound 30 (2.0 g, 5.59 mmol) in toluene (25 mL), 
and the reaction refluxed at 90 oC for 22 h. After concentrating under reduced 
pressure, the residue was purified by flash column chromatography (hexane:EtOAc = 
9:1) to afford the title compound as a white solid (2.0 g, 90%). 1H NMR (500 MHz, 
CDCl3) δ 4.42 (dd, J = 1.3, 6.3, 1H), 4.20 (dd, J = 1.4, 9.3, 1H), 4.14 (dd, J = 6.3, 9.3, 
1H), 3.78 (s, 3H), 2.18 – 2.03 (m, 2H), 1.67 (s, 2H), 1.63 – 1.57 (m, 2H), 1.54 (s, 3H), 
1.28 – 1.20 (m, 24H), 0.85 (t, J = 7.0, 3H). 13C NMR (126 MHz, CDCl3) δ 171.15, 
170.17, 96.62, 66.99, 59.49, 52.89, 35.64, 31.93, 29.70, 29.66, 29.64, 29.56, 29.48, 
29.37, 29.25, 25.15, 24.57, 23.57, 22.70, 14.13. MS (ESI) calculated for C23H43NO4, 










Synthesis of compound 32 ((S)-1-(4-(hydroxymethyl)-2,2-dimethyloxazolidin-3-
l)hexadecan-1-one).  
he ester functional group of 31 was reduced to the primary alcohol by first diluting 
thium borohydride (LiBH4; 2.0 M in THF, 1.89 mL, 3.77 mmol) in 5 mL of THF (5 
F 




mL) cooled to 0oC for 30 min. Comound 31 (500 mg, 1.26 mmol), dissolved in TH
(5 mL) was the
and then maintained at r.t. for an additional 6 h. After quenching the unreacted LiBH4 
with water, the reaction mixture was extracted with EtOAc (3X) and the combined 
EtOAc layers were washed by brine and dried over Na2SO4. The solvent was 
removed under vacuum and the resulting residue was purified by flash column 
chromatography (hexane:EtOAc = 4:1) to yield a white solid (489 mg, 81%). 1H 
NMR (500 MHz, CDCl3) δ 4.40 (s, 1H), 4.04 (d, J = 9.0, 1H), 4.01 – 3.88 (m, 2H), 
3.64 (d, J = 10.5, 2H), 2.39 – 2.26 (m, 2H), 1.62 (s, 2H), 1.59 (d, J = 17.8, 4H), 1.52 
(s, 2H), 1.25 (d, J = 22.7, 24H), 0.86 (t, J = 6.9, 3H). 13C NMR (126 MHz, CDCl3) δ 
170.41, 95.27, 65.43, 62.93, 58.55, 35.49, 31.94, 29.71, 29.68, 29.65, 29.54, 29.38, 
26.83, 25.20, 22.93, 22.71, 14.15. MS (ESI) calculated for C23H43NO4, m/z 369.58, 











Synthesis of compound 33 ((R)-1-(4-(iodomethyl)-2,2-dimethyloxazolidin-3-
yl)hexadecan-1-one). 
Compound 33 (151 mg, 97%) was obtained following the procedure described for the 
synthesis of 9. 1H NMR (400 MHz, CDCl3) δ 4.17 – 4.10 (m, 2H), 4.03 – 3.96 (m, 
1H), 3.26 (dd, J = 9.9, 11.4, 1H), 3.16 (dt, J = 2.5, 9.9, 1H), 2.34 – 2.16 (m, 2H), 
1.67-1.62 (m, 3H), 1.53 – 1.46 (m, 3H), 1.39 – 1.16 (m, 26H), 0.86 (t, J = 6.9, 3H). 







General procedure for S-alkylation: Synthesis of compound 34 (methyl 2-(tert-
butoxycarbonylamino)-3-(((R)-2,2-dimethyl-3-palmitoyloxazolidin-4-
yl)methylthio)propanoate). 
To a solution of 33 (300 mg, 0.63 mmol) in anhydrous DMF (8 mL) was added TEA 








Cys-OMe (1.03 g, 4.38 mmol). The reaction 
lution was stirred at 85oC for 2 h.  After removal of DMF under vacuum, the 
sidue was purified by flash column chromatography (hexane:EtOAc = 9:1) to afford 
4 as a viscous oil (356 mg, 97%). 1H NMR (400 MHz, CDCl3) δ 5.32 – 5.24 (m, 
H), 4.61-4.48 (m, 1H), 4.03 (d, J = 9.2, 1H), 3.95 – 3.89 (m, 1H), 3.87 – 3.81 (m, 







– 1.58 (m, 6H), 1.43 (s, 9H), 1.36 – 1.17 (m, 27H), 0.86 (t, J = 6.9, 3H). 13C 
(126 MHz, CDCl3) δ 171.10, 169.73, 155.02, 95.54, 80.37, 66.36, 57.42, 53.39, 
NMR 
ynthesis of compound 35 ((S)-methyl 3-tert-butoxy-2-((R)-2-(tert-
68 mmol) in 15 mL THF was de-esterified using 
52.79, 35.86, 35.49, 35.46, 31.92, 29.70, 29.69, 29.68, 29.66, 29.59, 29.37, 28.27, 
26.96, 25.08, 22.90, 22.70, 14.15. MS (ESI) calculated for C31H158N2O6S, m/z 586.40, 



















Compound 34 (400 mg, 0.
procedures as described for the syntheses of 12a-d with the exception that barium 
hydroxide octahydrate (645 mg, 2.04 mmol, in 6 mL H2O at 60 
oC, 1h), and not LiOH 
was used; we elected to use the much milder Ba(OH)2 conditions in view of potential 
lability of the amide bond in 34. Subsequent coupling to H-L-Ser(tBu)-OMe●HCl was 
carried out as described earlier for 12a-d. Compound 35 was obtained as a viscous oil 
(274 mg, 55%). 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 8.2, 1H), 5.40 (s, 1H), 
4.63 (d, J = 8.2, 1H), 4.35 – 4.24 (m, 1H), 4.11– 4.02 (m, 1H), 3.96 – 3,87 (m, 2H), 
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3.81 (dd, J = 2.8, 9.1, 1H), 3.74 – 3.69 (m, 3H), 3.54 (dd, J = 3.2, 9.1, 1H), 3.05 – 
2.94 (m, 1H), 2.93 – 2.79 (m, 2H), 2.77 – 2.67 (m, 1H), 2.38 – 2.23 (m, 2H), 1.61 (s, 
5H), 1.53 – 1.48 (m, 3H), 1.31 – 1.20 (m, 24H), 1.12 (s, 9H), 0.85 (t, J = 6.8, 3H). 13C 
NMR (126 MHz, CDCl3) δ 173.80, 170.63, 170.51, 170.02, 95.57, 80.38, 73.69, 
73.58, 66.43, 63.58, 61.68, 61.61, 57.45, 53.15, 52.50, 52.48, 51.49, 36.71, 35.40, 
5.13, 34.94, 32.92, 31.93, 30.95, 29.69, 29.66, 29.65, 29.54, 29.52, 29.38, 29.37, 
9.31, 28.32, 28.28, 27.30, 27.28, 26.96, 25.71, 25.16, 22.96, 22.70. MS (ESI) 














Synthesis of compound 36 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-
2,2-dimethyl-7,14-dioxo-12-(palmitoyloxymethyl)-3-oxa-10-thia-6,13-
diazanonacosane-5-carboxylate). 
The general procedure of acetonide deprotection and subsequent O-palmitoylation 
described earlier for the synthesis of 11 was utilized. The reaction residue was 
purified by flash column chromatography (hexane:EtOAc = 3:1) to afford the 
intermediate as a colorless oil. (203 mg, 80%). 1H NMR (500 MHz, CDCl3) δ 6.21 (d, 










J = 5.0, 11.3, 1H), 4.08 (dd, J = 4.9, 11.3, 1H), 3.81 (dd, J = 3.0, 9.1, 1H), 3.72 (s, 
3H), 3.55 (dd, J = 3.3, 9.1, 1H), 3.01 (dd, J = 5.5, 13.9, 1H), 2.91 – 2.79 (m, 2H), 
2.75 – 2.64 (m, J = 5.4, 14.0, 1H), 2.35 – 2.26 (m, 2H), 2.23 – 2.10 (m, 2H), 1.63 – 
1.55 (br s, 4H), 1.43 (s, 6H), 1.30 – 1.19 (m, 52H), 1.14 – 1.10 (m, 8H), 0.85 (t, J = 
7.0, 6H). 13C NMR (126 MHz, CDCl3) δ 173.90, 173.29, 170.59, 170.47, 155.40, 
80.21, 73.57, 64.46, 61.65, 53.72, 53.14, 52.47, 48.83, 36.70, 34.12, 31.93, 29.71, 
29.67, 29.55, 29.50, 29.46, 29.42, 29.37, 29.30, 29.27, 29.18, 28.31, 27.27, 25.65, 
24.88, 22.70, 14.15. MS (ESI) calculated for C51H97N3O9S, m/z 927.69, found 950.68 
+Na)+. 
ynthesis of compound 37 ((R)-3-((R)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-





















The previously described N-Boc/O-
d) was used. The title compound was obtained as a flaky yellow solid (99%). 1H 
NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 6.57 (s, 1H), 4.73 – 4.59 (m, 1H), 4.53 – 
4.34 (m, 1H), 4.34 – 4.23 (m, 1H), 4.23 – 4.15 (m, 1H), 4.15 – 4.06 (br s, 1H), 4.03 – 
3.84 (m, 2H), 3.79 – 3.67 (m, 3H), 3.21 – 2.93 (m, 2H), 2.90 – 2.63 (m, 2H), 2.37 – 





NMR (126 MHz, CDCl3) δ 174.32, 170.36, 170.21, 64.40, 53.13, 52.76, 52.64, 50.29, 
49.20, 36.61, 34.02, 31.94, 29.75, 29.73, 29.72, 29.70, 29.68, 29.60, 29.55, 29.38, 
29.34, 29.28, 29.23, 29.20, 29.12, 25.70, 24.85, 24.78, 22.70, 14.13. MS (ESI) 
calculated for C42H81N3O7S, m/z 771.58, found 772.59 (M+H)
+ and 794.57 (M+Na)+. 
 





ynthesis of compound 38 ((R)-methyl 2,2,11,11-tetramethyl-4,9-dioxo-3,10-
ioxa-5,8-diazadodecane-6-carboxylate). 
-2,3-diaminopropionic acid monohydrochloride (Sigma-Aldrich, 500 mg, 3.56 
A 
nt was 




mmol) was N-boc protected by Boc2O (2.33 g, 10.67 mmol) in the presence of TE
(1.49 mL, 10.67 mmol) in DCM (10 mL). After stirring at r.t. for 2 h, the solve
removed under vac
(DCM:MeOH = 17:3). The free carboxyl group of the intermediate was converted to 
methyl ester by dissolving it in anhydrous DCM (10 mL), followed by sequential 
addition of EDCI (1.11 g, 5.81 mmol), 1-hydroxybenzotriazole hydrate (HOBt; 785 
mg, 5.81 mmol), TEA (810 L, 5.81 mmol), anhydrous MeOH (353 L, 8.71 mmol) 
and a catalytic amount of DMAP. After stirring at r.t. for 10 h, solvent was removed 
from the reaction under vacuum and the reaction residue was dissolved in DCM, 
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washed with water (1X), brine (1X) and dried over Na2SO4. The residue was purified 
by silica flash chromatography (hexane:EtOAc = 22: 3) to afford the title compound 
38 (702 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 5.40 (s, 1H), 4.82 (s, 1H), 4.32 (s, 
1H), 3.73 (s, 3H), 3.56 – 3.40 (m, 2H), 1.44 – 1.39 (m, 18H). 13C NMR (126 MHz, 
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DCl3) δ 171.30, 156.13, 155.41, 80.14, 79.85, 54.17, 52.65, 42.40, 30.95, 28.29, 













Synthesis of compound 39 ((R)-tert-butyl 3-hydroxypropane-1,2-
diyldicarbamate).  
Sodium borohydride (NaBH4; 285 mg, 7.54 mmol) was added to a solution of 39 
(600mg, 2.20mmol) for reducing the ester to the corresponding primary alcohol. We 
used NaBH4 as an alternative to LiBH4 described in the synthesis of 32 with 
significantly better yields. The reaction mixture was refluxed at 75 oC and then 
anhydrous methanol (3 mL) was added dropwise over a period of 1 h. After refluxing 
for an additional 3 h, the reaction was acidified to pH 2.0 with 1 M HCl and THF was 
removed under vacuum. The residue was extracted with DCM (3X) and the combined 
DCM layers were washed with brine and dried over Na2SO4. The residue was purified 
by silica flash chromatography (hexane:EtOAc = 3:1) to yield 39 as a colorless oil 
(525 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 5.10 (s, 1H), 4.97 (s, 1H), 3.76 – 3.45 
(m, 4H), 3.41 – 3.16 (m, 2H), 1.58 – 1.36 (m, 18H). 13C NMR (126 MHz, CDCl3) δ 
157.75, 155.74, 80.41, 79.62, 61.56, 52.27, 40.12, 30.95, 28.36, 28.29. MS (ESI) 
calculated for C13H16N2O5, m/z 290.18, found 313.18 (M+Na)







Synthesis of compound 40 ((R)-tert-butyl 3-iodopropane-1,2-diyldicarbamate). 
 procedure essentially identical to that described for the synthesis of 9 was followed; 
. instead of at 90 
 minimize side-reactions and improve yield. No significant 
A
however the reaction was carried out at 0 oC and then warming to r.t
oC in an effort to
improvements in yield, unfortunately, were obtained.  Compound 40 was obtained as 
a white solid (489 mg, 71%). 1H NMR (400 MHz, CDCl3) δ 5.30 (s, 1H), 4.83 (s, 
1H), 3.62 (s, 1H), 3.44 – 3.21 (m, 4H), 1.46 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 
155.76, 154.44, 79.00, 50.54, 43.16 29.92, 27.31, 27.19, 7.69. MS (ESI) calculated 
for C13H25N2O4, m/z 400.09, found 423.09 (M+Na)















Synthesis of compound 41 ((6R,10R)-methyl 10-(tert-butoxycarbonylamino)-
1,1,1-trichloro-15,15-dimethyl-4,13-dioxo-3,14-dioxa-8-thia-5,12-
diazahexadecane-6-carboxylate). 
Orthogonal protection of the amines of the 2,3-diaminopropionic acid fragment, and 
f the amine of the cysteine unit was necessary. We elected to utilize Troc-L-Cys-
Me, which was obtained from L-cystine dimethylester (Sigma-Aldrich) as follows. 
,2,2-trichloroethyl chloroformate (805 L, 5.86 mmol) was slowly added to a 
irring solution of L-cystine dimethylester dihydrochloride (500 mg, 1.47 mmol) in 
s 
eme 6, 
ep d) is provided in the Supplemental Data. S-alkylation of Troc-L-Cys-OMe with 
0 was performed as described earlier for 26. Compound 41 was obtained as a 
ixture with the oxidized N-Troc cystine dimethylester as ascertained by LC-MS and 
ponents were virtually identical, rendering the isolation 





anhydrous DCM (10 mL) and pyridine (10 mL) cooled to 0 oC. The reaction wa
brought to r.t. and stirred for 8 h. After removal of solvent under vacuum, the residue 
was purified by flash chromatography (hexane:EtOAc = 4:1) to afford N-Troc cystine 
dimethylester as a white solid. The disulfide bond of the N-Troc-protected cystine 
ester was reduced by dissolving the solid in THF (10 mL), and adding 
tributylphosphine (Bu3P; 542 L, 2.20 mmol) and H2O (132 L, 7.33 mmol).217 The 
reaction was stirred at r.t. for 2 h. After removal of solvent, the residue was purified 
by flash column chromatography (hexane:EtOAc = 9:1) to afford the title compound 




1H NMR. The Rfs of both com
 138
several solvent combinations also did not yield good separations.  We reaso
however, that N-Troc cystine dimethylester would be inert 
deprotection and N-acylation cond
ned, 
to both N-Boc 
itions that were to follow (see synthesis of 42 






Synthesis of compound 42 ((6R,10R)-methyl 1,1,1-trichloro-4,13-dioxo-10-
palmitamido-3-oxa-8-thia-5,12-diazaoctacosane-6-carboxylate). 
A crude sample of 41 (200 mg, 0.34 mmol) was dissolved in excess dry TFA and 
stirred at r.t. for 30 min to effect N-Boc deprotection on the 2,3-diaminopropionic 
acid fragment. Excess TFA was removed by purging nitrogen. The resulting diamino 
intermediate was coupled with palmitic acid (264 mg, 1.03 mmol) using EDCI (197 
mg, 1.03 mmol), HOBt (139 mg, 1.03 mmol) and TEA (287 mL, 2.06 mmol), and a 
catalytic amount of DMAP in anhydrous DMF (8 mL). The reaction was stirred at 60 
oC for 10 h. After DMF was removed under reduced pressure, the residue was 
dissolved with DCM and washed with water (1X), brine (1X) and dried over Na2SO4. 
The residue was purified by silica flash chromatography (hexane:EtOAc = 39:11) to 
afford the title compound 42 (185 mg, 64%). 1H NMR (500 MHz, CDCl3) δ 6.90 (d, J 













(m, 1H), 3.98 (br s, 1H), 3.76 (d, J = 4.3, 3H), 3.53 – 3.43 (m, 1H), 3.41 – 3.30 (m, 
1H), 3.12 – 2.97 (m, 2H), 2.92 – 2.78 (m, 2H), 2.57 – 2.43 (m, 1H), 2.23 – 2.09 (m, 
4H), 1.63 – 1.50 (m, 4H), 1.22 (s, 48H), 0.85 (t, J = 6.9, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.07, 171.90, 168.27, 151.86, 92.87 72.24, 52.01, 50.44, 48.60, 34.42, 
4.16, 32.08, 31.71, 29.48, 27.27, 27.24, 27.22, 27.10, 27.07, 26.92, 26.85, 23.17, 
0.25, 11.69. MS (ESI) calculated for C42H78Cl3N3O6S, m/z 857.47, found 880.45, 










Synthesis of compound 43 ((6R,10R)-methyl 2,2-dimethyl-4,13-dioxo-10-
palmitamido-3-oxa-8-thia-5,12-diazaoctacosane-6-carboxylate).  
The base-labile N-Troc protecting group on the cysteine unit had to be converted to 
the N-Boc derivative in order to carry out subsequent base-catalyzed de-esterfication 
step (see synthesis of 44 below). Accordingly, 42 (350mg, 0.41 mmol) was dissolved 
in THF (3 mL) and zinc dust (266 mg, 4.07 mmol), AcOH (15 mL) and H2O (1 mL) 
was added to the reaction. After stirring at r.t. for 1 h, zinc was filtered on celite and 
the filtrate was concentrated under reduced pressure. Reprotection with Boc2O was 
achieved by dissolving the completely dried intermediate in DCM and the addition of 












stirring the reaction mixture at r.t. for 1h.  After the solvent was removed, the residue 
was purified by silica flash chromatography (hexane:EtOAc = 7:3) to yield the 
desired product 43 as a white solid (217 mg, 68%). 1H NMR (400 MHz, CDCl3) δ 
6.81 (s, 1H), 5.43 (s, 1H), 4.55 (s, 1H), 4.03 (s, 1H), 3.82 – 3.77 (m, 3H), 3.53 (s, 
1H), 3.42 (s, 1H), 3.11 – 2.86 (m, 3H), 2.30 – 2.13 (m, 4H), 1.69 – 1.56 (m, 4H), 1.54 
– 1.44 (m,7H), 1.27 (s, 48H). 13C NMR (126 MHz, CDCl3) δ 173.14, 141.89, 169.32, 
169.22, 78.11, 72.52, 51.39, 50.52, 48.69, 48.31, 40.02, 39.64, 34.60, 34.46, 33.77, 
3.19, 32.16, 29.76, 27.55, 27.52, 27.50, 27.38, 27.36, 27.21, 27.17, 27.14, 27.12, 
6.13, 23.57, 23.50, 23.48, 23.37, 20.53. MS (ESI) calculated for C44H85N3O6S, m/z 











Synthesis of compound 44 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-
2,2-dimethyl-7,15-dioxo-12-palmitamido-3-oxa-10-thia-6,14-diazatriacontane-5-
carboxylate). 
De-esterification followed by serine coupling was carried out as described for the 
synthesis of 35. (75%) 
1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 6.52 (s, 1H), 5.52 (s, 1H), 4.68 – 4.61 (m, 














2H), 2.98 – 2.83 (m, 2H), 2.23 – 2.09 (m, 4H), 1.65 – 1.51 (m, 4H), 1.46 – 1.40 (m, 
8H), 1.22 (s, 48H), 1.14 – 1.09 (m, 9H), 0.85 (t, J = 6.8, 6H). 13C NMR (126 MHz, 
CDCl3) δ 174.15, 173.17, 169.65, 169.56, 154.54, 79.12, 72.61, 60.69, 52.18, 51.40, 
50.55, 41.27, 35.75, 35.61, 30.91, 29.92, 28.69, 28.66, 28.65, 28.54, 28.52, 28.39, 
28.38, 28.35, 28.32, 28.30, 27.32, 27.29, 26.26, 24.76, 24.67, 21.67, 13.11. MS (ESI) 
















.20 – 7.11 (m, 1H), 4.70 – 4.54 (m, 1H), 4.51 – 4.37 (m, 1H), 3.90 (s, 
, 3H), 1.53 (s, 3H), 1.25 (d, J = 21.5, 49H), 0.85 (t, J = 6.9, 
d
tr
Compound 45 was deprotected with TFA as described earlier. The title compoun
were obtained as a flaky yellow solid (99%). 1H NMR (500 MHz, CDCl3) δ 7.21 –
7.11 (m, 1H), 7
2H), 3.71 (s, 3H), 3.49 – 3.35 (m, 1H), 3.33 – 3.22 (m, 1H), 3.21 – 3.01 (m, 1H), 2.80 
– 2.53 (m, 1H), 2.15 (s
6H). 13C NMR (126 MHz, CDCl3) δ 132.65, 131.11, 129.02, 68.37, 52.91, 38.92, 
36.93, 36.56, 36.55, 32.15, 30.56, 30.37, 29.97, 29.88, 29.83, 29.76, 29.68, 29.60, 
HN
S











29.56, 29.54, 29.51, 29.47, 29.46, 29.13, 25.98, 25.86, 25.77, 23.94, 23.20, 22.92, 
14.41, 14.34, 14.28, 11.17. MS (ESI) calculated for C42H82N4O6S, m/z 770.60, found 
771.60 (M+H)+.  
 
4.7.2 Materials and Methods 
4.7.2.1 Chemistry: See 2.6.1.1 
4.7.2.2 Assays 
F-B induction: The induction of NF-B was was performed in HEK cells stably 
ansfected with human TLR2 using procedures described in section 2.6.1.2. 
itric Oxide Assay: See 2.6.1.2 
ts of fresh whole 
 healthy human 






Phosflow™ flow cytometric assay for p38MAPK: One ml aliquo
blood, anticoagulated with heparin (obtained by venipuncture from
volunteers with in
Subjects Experimentation Committee) were incubated with 25 l of a mix of 8 g/ml 
of E. coli 0111:B4 LPS and graded concentrations of test compounds diluted in saline 
(typically serially diluted from 80 M) for 15 minutes at 37oC. This resulted in final 
concentrations of 100 ng/ml of LPS and 1 nM of compound (at the lowest dilution). 
Positive (LPS alone) and negative (saline) controls were included in each experiment. 
Erythrocytes were lysed and leukocytes were fixed in one step by mixing 200 l of 
the samples in 4 ml pre-warmed whole blood lyse/fix Buffer (Becton-Dickinson 
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Biosciences, San Jose, CA). After washing the cells at 500 x g for 8 minutes in CBA 
buffer, the cells were permeabilized in ice-cold methanol for 30 min, washed twice in 
CBA buffer and transferred to a Millipore MultiScreen BV 1.2  filter plate and 
ained with either phycoerythrin (PE)-conjugated mouse anti-p38MAPK 
es) mAb, or a matched PE-labeled mouse IgG1  
nutes. The cells were washed twice in the plate by 
r protocols supplied by the vendor. Cytometry was performed using a 
software 
reestar, Ashland, OR).  
ultiplexed cytokine assay ex vivo in human blood: See 2.6.1.2 
st
(pT180/pY182; BD Bioscienc
isotype control mAb for 60 mi
aspiration as pe
BD FACSArray instrument in the single-color mode for PE acquisition on 20,000 





Pyrogenicity response assay: Adult New Zealand White rabbits were administered 
intravenously saline (negative control), LPS (200 ng/kg), or varying doses of 
PAM2CSK4 (10, 50, or 200 g/kg) and their core temperatures were monitored for 3 
hours using an indwelling rectal thermometer connected to an electronic temperature 
recorder.  All experiments were performed in accordance with animal care protocols 
approved by the University of Kansas IACUC Committee. 
 
Flow-cytometric immunostimulation experiments: Heparin-anticoagulated whole 
blood samples were obtained by venipuncture from healthy human volunteers with 
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informed consent and as per guidelines approved by the University of Kansas Human 
Subjects Experimentation Committee. A minimum of six blood samples obtained 
from individuals of both sexes and diverse ancestry were analyzed for each 
experiment. Two mL aliquots of whole human blood samples were stimulated with a 
final concentration of 1 g/mL of one of the various stimuli under study in a 6-well 
polystyrene plate and incubated at 37oC in a rotary (100 rpm) incubator for 16.5 h. 
Negative (endotoxin free water) controls were included in each experiment.  
Following incubation, 200 µL aliquots of anticoagulant whole blood were stained 
with 40 L of fluorochrome-conjugated antibodies at 37oC in the dark for 30 min. For 
triple color flow cytometry experiments, CD3-PE, CD56-APC, CD69-PE-Cy7 were 
sed to analyze CD69 activation of each of the main peripheral blood lymphocyte 
 cytokine-induced 
iller phenotype (CIK cells: CD3+CD56+), nominal B lymphocytes (CD3-CD56-), and 
ces, San Jose, CA). After 
ashing the cells twice at 200 g for 8 minutes in saline, the cells were transferred to a 
u
populations: natural killer lymphocytes (NK cells: CD3-CD56+),
k
nominal T lymphocytes (CD3+CD56-). These experiments were complemented with 
separate experiments using PE-CD3, APC-CD4 (CD4+ T lymphocytes)/ APC-CD8 
(CD8+ T lymphocytes)/APC-CD19 (B lymphocytes), in combination with PE-Cy7-
conjugated CD69 antibodies.  Following staining, erythrocytes were lysed and 
leukocytes fixed in one step by mixing 200 L of the samples in 4 mL pre-warmed 
Whole Blood Lyse/Fix Buffer (Becton-Dickinson Bioscien
w
96-well plate.  Flow cytometry was performed using a BD FACSArray instrument in 
the tri-color mode (tri-color flow experiment) and two-color mode (two-color flow 
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experiment) for acquisition on 100,000 gated events. Post-acquisition analyses were 
performed using FlowJo v 7.0 software (Treestar, Ashland, OR). Compensation for 
spillover was computed for each experiment on singly-stained samples. Statistical 
significance of data were analyzed using both two-way ANOVA with Bonferroni 
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